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damage to the salivary glands 
1 In het rattenmodel biedt voorbehandeling met pilocarpine na een eenmalige 
bestraling beschem1ing tegen stralingsschade aan de glandula parotis ( dit 
proefschrift). 
2 Pilocarpine is geen klassieke radioprotector maar een stimulator van de 
celproliferatie in de bestraalde en de afgeschermde speekselklier (dit 
proefschrift). 
3 Hoewel het verzamelen van speeksel van de glandula parotis met Carlson­
Crittenden cupjes in de literatuur als gouden standaard wordt gezien, kan de 
spreiding van deze meetmethode onder standaard condities aanzienlijk zijn 
(dit proefschrift). 
4 Bij patienten die pilocarpine tijdens de bestraling krijgen toegediend wordt, 
bij een gemiddelde bestralingsdosis van meer dan 40 Gy op de glandula 
parotis, een beschermend effect op de glandula parotis gevonden (dit 
proefschrift). 
s Gezien de superieure bundeleigenschappen van protonen hebben patienten 
die met protonen worden behandeld minder kans op stralingsschade dan na 
een behandeling met fotonen. 
6 De lat heel hoog leggen biedt vooral garantie voor ongeluk (Prof. Dr. Bas 
Haring). 
7 Anno 2008 heeft de radiotherapie bewezen leidend te zijn binnen de 
oncologie. 
8 De waarheid in het medische vak heeft een beperkte houdbaarheidsdatum. 
9 Veel medisch specialisten moeten nog accepteren dat hun rol binnen de 
gezondheidszorg aan het veranderen is. 
10 Wanneer je het liefst zou will en opgeven, ben je het dichtst bij je doel. 
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and aim of the thesis 
Introduction Radiation-induced xerostomia is one of the most frequently reported side-effect amongst patients treated for a head and neck cancer. Xerostomia is often accompa­nied with an impairment of essential functions as chewing, taste, swallowing and speech. Moreover, these patients are more susceptible to development of oral infec­tions and dental decay. Xerostomia and its related complaints also have a large impact on quality of life. In addition, xerostomia has been reported by patients as one of the most serious side-effect of radiation [1;2]. To further reduce radiation induced xerostomia in patients in whom new radiation delivery techniques do not provide sufficient sparing of the salivary glands, there is a need for other treatment approaches to ideally prevent loss of salivary gland function or at least reduce the radiation-induced drop in salivary secretion. Some of these approaches are studied in this PhD thesis. Moreover, a short introduction in the anatomy of the salivary glands and physiology of salivary secretion is added to this chapter for a better understanding of which treatment approaches might potentially exert a sparing effect on irradiation-damage to salivary gland tissue. 
Anatomy of the salivary glands In the head and neck region, the major and minor salivary glands provide the mixed fluid in the mouth called whole saliva. Beside the numerous minor salivary glands located just beneath the oral mucosa, there are three, paired, major salivary glands (parotid, submandibular, sublingual) responsible for 90% of the saliva production. In the resting state, two-third of whole saliva consists of submandibular saliva. During eating or stimulation parotid saliva accounts for more then half of the saliva volume. Although the minor salivary glands produce only a small proportion of the saliva, it contains a large fraction of the salivary proteins and plays a very important role in the lubrication of the mucosa. Saliva is produced by the acinar cells, in the secretory end pieces, then moves into the intercalated ducts, the striated ducts and finally the excretory ducts. Around the 
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acinar cells and the intercalated ducts, myoepithelial cells promote the flow of saliva into the ducts. The intercalated ducts are believed to contain the stem/progenitor cells for the acinar and the ductal cell types. The striated ducts consist of columnar cells with deep membrane infolding and many mitochondria. These duct cells modify the composition of the primacy saliva as formed by the acinar cells to the saliva as it is secreted into the oral cavity. The regulation of salivary secretion by reflexes involves the autonomic nervous sys­tem, both the sympathetic and the parasympathetic nerves. Afferent nerves carry impulses to salivary nucleus in the medulla. From here efferent signals are directed to the salivary glands. Also afferents arising from the olfactorium and stretch of the stom­ach can initiate salivation. The sympathetic nerves run from the sympathetic trunk, follow the blood vessels supplying the glands and then separately innervate the glands. The parotid gland receives parasympathetic signals from the signals from the glos­sopharyngeal nerve; the submandibular and sublingual glands receive parasympa­thetic signals from the facial nerve [3;4]. 
Physiology of the salivary glands Saliva is basically formed in two steps; primacy saliva formed in the secretory end­pieces (acinar cells) with an isotonic composition similar to that of plasma. The pri­macy saliva is modified in the duct system, especially the striated ducts, by absorption of, amongst others, Na+ and HCO3-, and the secretion ofH+ and some K+, forming the final saliva secreted in the mouth. The volume of the final saliva is determined by the formation rate of the primacy saliva by the acinar cells, which is the result of an active transport of solutes by the acinar cell. The secretion of saliva is regulated by reflexes involving the autonomic nervous system. The secretion of water, electrolytes and the exocytotic release of proteins involves a multitude of biochemical signalling processes. The key event is the rise of intracellular Caz+ initiated by activation of the receptors in the plasma membrane by neurotransmitters. The a1-adrenergic receptor is activated by noradrenaline, the muscarinic receptor by acetylcholine and the p-adrenergic receptor by noradrenaline/adrenaline. Beside the two classical neurotransmitters other substances are co-released such as adeno­sine tri-phosphate (ATP), substance P, vasoactive intestinal peptide (VIP) and neu­ropeptide Y. The a1-adrenergic receptor and the muscarinic receptor both are G protein-coupled receptors of the Gq/11 type. Binding induces phospholipase C-medi­ated hydrolysis of the plasma membrane component phosphoinositol bi phosphate (PIP2) that forms the second messenger's inositol triphosphate (IP3) and diacylglyc­erol (DAG). IP3 binds to specific IP3-receptors on the endoplasmatic reticulum that INTRODUCTION AND AIM 19 
induces Ca2+ release from this store within the cell, giving rise to an increase in the free intracellular Ca2+. This pathway is important for the initiating the electrolyte transport. Another G-protein-coupled receptor signalling pathway that leads to an increase in the intracellular free Ca2+, is the j3-adrenergic activation of a Gs-protein and adenylate cyclase, which elicits the synthesis of cyclic adenosine monophosphate (cAMP). This cAMP then activates protein kinase A, which in turn causes intracellular Ca2+ to increase. The cAMP pathway is involved in the protein synthesis in the rough endo­plasmatic reticulum and in exocytosis of protein-containing secretory granules across the cell membrane. Protein synthesis and secretion also occurs as a consequence of DAG formation, this activates protein kinase C. Protein secretion from the salivary glands is a continuous so called 'constitutive exocytosis' of protein containing vesicles. This process can be accelerated by the regulated exocytosis controlled by the duel parasympathetic and sympathetic secretomotoric innervation. The minor salivary glands secrete protein rich secretion continuously. The blood vessels are controlled by the sympathetic nerves which make them constrict. Parasympathetic stimulation over­comes this vasoconstriction and gives vasodilatation. Radiation damage may be due to interference of this complex regulation mechanism in the cell, due to vascular damage or cell death. 
Methods to reduce radiation damage to salivary gland tissue Radiation damage to salivary gland tissue due to treatment of a head and tumour located outside the salivary glands can be minimized by reducing the cumulative radi­ation dose to the glandular tissue by applying up to date radiation schedules and equipment. However, even then the salivary glands are subjected to at least to some degree of radiation damage. Thus, there is a need for methods to reduce the sensitiv­ity of salivary glands to ionizing radiation and a need for tools to reduce the burden of hyposalivation by either effective supportive oral care or by methods to regenerate diseased salivary gland tissue. Common methods that are applied include the appli­cation of modern techniques as intensity-modulated radiotherapy (IMRT) [5-15]. Another option is the use of other radiation beams like protons [16] and the applica­tion of agents with the intent to reduce the radiation damage to the salivary glands (e.g., amifostine, pilocarpine) [17-27) or to increase the recovery of salivary gland tissue from radiation damage (e.g. pilocarpine) [28-35). Moreover, innovative methods are currently developed to recover the function of a salivary gland damaged by ionizing radiation, viz. gene therapy to induce the expression water channels in the salivary secretory cells damaged by radiation [36-40) and regenerative techniques using stem 
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cells transplantation or stem cells mobilization to regenerate the injured salivary gland tissue [41]. With regard to gene therapy the first trial in human has recently been started in the USA, regarding stem cells transplantation and mobilization prom­ising results have been obtained in mice. Unfortunately, gene therapy and stem cell research are still at an experimental level and not yet generally applicable in human. Moreover, the radical scavenger amifostine, although shown to be able to slightly reduce radiation-induced xerostomia, is accompanied by high costs and high patient morbidity [42]. Therefore, the PhD research in this thesis was focussed on the applica­bility of pilocarpine in reducing radiation-damage to salivary gland tissue. Pilo­carpine is a drug with low costs and its usage is well accepted by most patients. Moreover, in animal experiments pilocarpine has been shown to exert a sparing effect on radiation damage to salivary gland tissue [43-47]. In human it also was shown that certain, not well defined, patient cohorts subjected to a full course of radiotherapy for head and neck cancer benefited from the use of pilocarpine given concomitant with the course or radiotherapy. 
Aim of the thesis The overall aim of this PhD research project was to study the efficacy of pilocarpine in reducing radiation-induced xerostomia in a series of preclinical and clinical studies. The specific aims of this PhD project were: ■ To review the literature regarding the effect or radiotherapy to normal tissues in the head and neck region, with emphasis on radiation injury to the salivary gland tissue and methods applied to reduce the radiation injury this tissue (Chapter 2). ■ To determine, in a rat model, the effectiveness of pilocarpine in reducing radiation damage to salivary gland tissue using functional and histopathological assessments (Chapter 3). ■ To elucidate the mechanism of reduction of radiation-induced damage by pilo­carpine as this mechanism, at least in part, might be the result of stimulating cell proliferation of undamaged salivary gland cells. Using Proliferating Cell Nuclear Antigen (PCNA) labelling, cell proliferation was evaluated in a group of rats irradi­ated, either with or without pilocarpine pre-treatment (Chapter 4). ■ To validate the accuracy of selective parotid saliva collection, by using Carlson-Crit­tenden cups, in a group of healthy volunteers and patients with Sjogren's syndrome 
INTRODUCTION AND AIM 111 
saliva samples were collected at the same time of the day (Chapter 5). This study was performed to obtain insight into the intra-patient and interobserver variation of repeated collections of parotid saliva. Such information is essential when develop­ing a clinical trial aimed to assess the efficacy of pilocarpine in reducing radiation­induced hyposalivation. ■ To access the early changes in salivary flow during and immediately after irradia­tion, both of the parotid and the submandibular/sublingual glands (Chapter 6) as there is inconsistency in the literature regarding the radiosensitivity of the various types of salivary gland tissue. Such information is essential planning trials to reduce the radiation-induced damage to salivary glands. ■ To assess in a double blind, randomized, placebo controlled, multicentre study, the objective and subjective efficacy of pilocarpine given concomitant with a full course of radiotherapy for head and neck cancer in reducing the resulting xerostomia and related complaints (Chapter 7). As the sparing effect of pilocarpine might be related to the dose-volume distribution of the applied radiotherapy in parotid gland tissue, a factor that was insufficiently covered by the other studies published in the litera­ture thus far, patients were stratified according to the parotid volume that received a dose of at least 40 Gy. The primary endpoint of this study was defined as a relative reduction in the salivary flow exceeding the intra-patients and inter-observer varia­tion of repeated collection of parotid saliva as determined in chapter 5. Secondary endpoints were the subjective complaints related to radiation-induced xerostomia using the LENT SOMA score and a patient-rated xerostomia score with a Numerical Analogue Scale. 
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Chapter 
Review of the literature This chapter is a compilation of the papers listed below: 
VISSINK A, JANSMA J, SPIJKERVET FKL, BURLAGE FR, COPPES RP. Oral sequelae of 
head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212. 
VIS SINK A, BURLAGE FR, SPIJKERVET FKL, JANSMA JI COPPES RP. Prevention and treat­
ment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 
2003;14:213-225. 
VISSINK A, BURLAGE FR, SPIJKERVET FKL, VEERMAN ECI, VAN NIEUW AMERONGEN 
A. Prevention and treatment of salivary gland hypofunction related to head and neck 
radiation therapy and chemotherapy. Supportive Cancer Therapy 2004;1:111-118. 
Introduction The oral tissues are frequent sites of complications arising from radiotherapy, including mucositis, xerostomia, osteoradionecrosis and local infections [1-4]. Because of the reduction in salivary secretion, a number of essential functions is impaired that may result in difficulties with chewing, swallowing and speech, oral inflammations, dental decay and changes of taste-perception [3-5]. As it is not a life threatening issue in a serious disease as cancer is, xerostomia is often positioned as an orphan topic in supportive care [6;7]. Nevertheless, xerostomia has an impact on the quality of life: without saliva many patients suffer from persistent daily discom­fort, which negatively influences their social life [8;9]. Up to now there is no effective method to prevent damage caused by radiother­apy in all patients that has surpassed the research level and is generally clinically applicable. There are clinical trials indicating a potential beneficial effect of radi­cal scavengers, like amifostine [10-18] and saliva stimulants like pilocarpine [19-23]. Other developments are gene transfer to regain the salivary glands its function and stem cell transplantation to regenerate a diseased salivary gland [24;25]. Currently, the best way to reduce radiation damage is to spare the salivary glands as much as possible with new irradiation techniques including intensity-modulated radiother­apy (IMRT) [9;26-35]. Notwithstanding the above mentioned new developments with potential future clinical applicability, currently the effects of irradiation on salivary gland tissue are still irreversible to a large extent and will give rise to serious complaints in a substantial number of patients, treated for a head and neck carcinoma. There are various methods by which xerostomia complaints can be alleviated, either by stimulation of residual salivary gland secretory potency ( e.g. chewing, taste stimuli, pharmacological agents) or by wetting of the oral tissues if the residual potency is negligible (e.g. mouthrinses, saliva substitutes). In patients, nocturnal oral dryness can be alleviated by moistening the oral surfaces with water or by applying a saliva substitute, particularly a substitute with gel-like properties. During daytime, the application of mouthrinses or saliva substitutes is indicated if moistening of the oral surfaces with water is not sufficient. More recent innovations for clinical 
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application are bioactive saliva substitutes and mouthrinses containing antimicrobial peptides to protect the oral tissues against microbial colonization and to suppress or cure mucosal and gingival inflammation. 
The role of radiotherapy in head and neck cancer Radiotherapy plays an important role in the management of head and neck cancer. The majority of new cases of invasive head and neck cancer needs radiotherapy as a primary treatment, as an adjunct to surgery, in combination with chemotherapy, or as palliation. Tolerance of the adjacent normal tissues is the most important dose-limit­ing factor. Depending on stage and location of the primary tumour and affected lymph nodes, the oral cavity and salivary glands of most head and neck cancer patients are at least to some extent located in the radiation portals. Even with the most optimal fractionation schedule and radiation techniques, unwanted radiation­induced changes will occur in these tissues [4]. As the overall five years survival for head and neck cancer survival is about 80% for the early stages and about 35% for more advanced stages, the objective of effective cancer treatment includes achieving locoregional control with preservation of normal tissue function and reducing injury as much as possible. The prescribed radiation dose is based on location and type of malignancy, and whether or not radiotherapy will be given alone or in combination with other modali­ties. Most patients with head and neck carcinomas, treated with a curative intent, receive a total absorbed dose between 46 and 70 Gy. This dose is usually administered over a five to seven week period, once a day, five to six times a week, 2 Gy per fraction. Several strategies to further increase locoregional tumour control without increasing the normal tissue complication probability have been developed and are tested in clini­cal trials or are already implemented in daily clinical practice. These strategies include altered fractionation schemes like hyperfractionation and accelerated fractionation or chemoradiation [36;37] and treatment to increase tumour oxygenation (ARCON) [38]. These new treatment strategies show either the same or an increased acute toxicity, without significantly increasing late morbidity. In addition, techniques that reduce the irradiated volume (3D conformal radiation therapy and IMRT) and thus can spare the normal tissues to a greater extent, shortly will become the new standard in daily clinical practice [9;26-35]. 
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Objective quantification of xerostomia Xerostomia is the subjective feeling of dry mouth, which is not necessarily linked with a significant reduction in salivary flow. It is therefore essential that, in addition to an assessment of the subjective complaints, the hypofunction of the salivary glands in such patients is substantiated by measuring the saliva secretion rate before, during and after radiotherapy and/or chemotherapy. Hereby the physician gets more insight in the change of function of the salivary glands during the course of the therapy and the patient becomes more conscious of the causes of the oral dryness. In this way both the physician and patient become more motivated to prescribe and use a ther­apy aimed to stimulate the salivary flow using relatively simple methods (e.g. chewing etc). Salivary flow rates of whole pooled saliva (that can be collected by e.g. a drooling or spitting method) and glandular saliva (separate collection of secretions of the parotid and/or submandibular/sublingual glands) can be obtained without stimula­tion (resting saliva) and after mechanical (chewing) or gustatory (e.g. citric acid) stim­ulation. In this way it can be easily deducted whether sufficient saliva is secreted under resting conditions. These conditions are present in the oral cavity during the major time of the day and overnight. In addition, assessment of the functional potency of the salivary glands shows to what extent stimulation of the salivary flow is possible [39;40], which salivary glands still can be stimulated to a significant flow and in which cases supportive oral care (stimulation therapy) might be successful. When adequate stimulation of saliva flow is not possible, only palliative oral care can be provided [41-43]. Assessment of the salivary gland function by scintigraphy has a reasonable correla­tion with the measured salivary output [44;45]. However lack of correlation with xerosto­mia-rated questionnaires has been reported [46]. Scintigraphy does however give both functional and spatial information of the salivary glands activity. Because of the tech­nical difficulties scintigraphy is not the routine investigation for the assessment of hyposalivation. Although fractionated saliva collection using Lashley cups is often regarded as the golden standard, little is known about the variation and sampling error of this method. This information is vital calculating the number of patients needed in a clini­cal study, investigating a new strategy. Therefore, we strongly suggest that, from a clinical point of view, the combination of objective (measurement of salivary flow rate) and subjective (questionnaires) parameters still provides the best assessment with regard to the pattern of patients' complaints and the effects of various therapies on these complaints. 
20 I CHAPTER 2 
Mechanism of radiation damage to the salivary glands ANIMAL STUDIES Detailed kinetic studies in rat parotid salivary gland tissue by Coppes et al. [47] revealed the existence of four phases in the radiation-induced loss of salivary gland function in rats. The first phase (0-10 days) was characterised by a rapid decline in flow rate with­out changes in amylase secretion or acinar cell number. The second phase (10-60 days) consisted of a decrease in amylase secretion and was paralleled by acinar cell loss. Flow rate, amylase secretion and the number of acinar cell did not change during the third phase (60-120 days). The fourth phase (120-240 days) was characterised by a fur­ther deterioration of gland function accompanied with an increase in the number of acinar cell, albeit with poor tissue morphology. Comparable changes have been observed in rat submandibular tissue [48;49]. The early response in gland function has been studied thoroughly in rats [47;48;50-
55]. Within three days after irradiation with a single dose of 15 Gy of X-rays, a decrease in salivary flow of near 50% can be observed [47;48;50;53;54;56]. Lack of obvious quantita­tive morphological alterations [48;51;55;57], a rather quick recovery of those minor mor­phological changes that do occur [58] and few apoptotic cells early after radiotherapy 
[59], point to the presence of non-removed dysfunctional cells at the level of mem­branes [60-62] and/or a disturbed intracellular signalling [54;58]. This is thought to be the cause of the effect of radiation on the parotid gland in the first phase after treat­ment. This was supported by an in vitro study showing that muscarinic receptor­induced calcium mobilisation and protein kinase C activation was affected early after radiation [63]. Whereas phase 2 is clearly related to the normal cell turnover being impaired after radiation, followed by a steady state level of residual function in phase 3, in phase four a depletion of surviving progenitor cells will lead to further depletion of acinar cells and further detoriation of the gland function. The late effects of radiation on the parotid and submandibular glands show a clear dose-dependent further decline in function [47;64] and further loss of acinar cells 
[57;65]. Unfortunately, however, in the latter studies parts of the head and mouth were included in the radiation field. Therefore, indirect effects due to damage to other organs confound the interpretation with regards to salivary gland function [66-69]. HUMAN STUDIES Based on the slow turnover rates of their cells, the salivary glands are expected to be late responding and relatively radioresistant [70]. Yet, the changes in quantity and com­position of saliva that occur shortly after radiotherapy indicate that the gland tissue is an acutely responding tissue with a high radiosensitivity [62;71-7 4]. It is not clear 
REVIEW OF THE LITERATURE 1 21 
whether the direct effects of radiation on the secretory and ductal cells cause radiation damage of salivary gland tissue/cells, or if it is secondary to injury of the fine vascular structures, increased capillary permeability, interstitial oedema and inflammatory reaction. In a human post-mortem study, it has been assessed that in the lower dose range ( < 30 Gy) damage is reversible to a certain level, but after cumulative doses of > 75 Gy, extensive irreversible degeneration of acinar cells is observed along with inflam­mation and fibrosis in the interstitium [75]. Serous acinar cells appear to be more readily affected by irradiation than mucous acinar cells and ductal cells [76]. From histological experiments with rhesus monkeys, irradiated on the parotid gland with single doses of 2.5-10 Gy, it was concluded that the acute functional impairment was caused directly by serous acinar apoptotic cell death rather than being the result of inflammatory processes and circulatory compromise due to vascular injury [77]. Other animal data suggested that late loss of function is not due to chronic inflammation or fibrosis of the glandular tissue [65]. The reason for this inconsistency with the human data is unclear; differences in dose and volume effects as well as timing of events may all play a role. In patients, depending on the localisation of the radiation portals, a rapid decrease of the salivary flow rate is observed during the first week of radiotherapy, after which there is a gradual decrease to less than 10% of the initial flow rate [51;73;78-82]. Although in the older literature the submandibular gland was thought to be less radiosensitive than the parotid gland, in clinical practice both glands have been shown to be as sensi­tive to radiotherapy, at least with respect to their function [73;80;81]. In rats, it has been shown that the submandibular gland may be even more sensitive for the late effects of radiation due to inability to restore the damage [49], but it remains to be established if this is true for humans. The human data on radiation-induced drop in flow rate of both the parotid and submandibular gland are somewhat in contradiction to the data derived from scinti­graphic studies [46;83]. These authors showed a failure of the major salivary glands to excrete saliva early post-irradiation, and a decreased uptake of 99mTc-pertechnetate together with a loss of secretory function in the post-irradiation stage. This effect was stronger in parotid than in sub mandibular glands, although the incidence of xerosto­mia did not correlate with the effects observed in the scintigraphic studies [46], once again pointing to the obvious discrepancy between the actual salivary flow and the scintigraphic [46] and the morphological changes [58] induced by irradiation. 
It has been suggested that the final degree of radiation-induced hyposalivation depends on individual patient characteristics, such as pre-irradiation salivary gland activity, age and sex [84-86]. It has been stated that salivary glands with high flow rates before starting radiotherapy show less reduction in salivary flow rate [84-87], but this observation could not be confirmed in recent dose-volume studies [88-90]. 
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More important is the observation that the irradiated volume of salivary gland tis­sue correlates directly with the severity of oral complications [9;28-35;44;82;86;88-94]. Recent prospective studies of salivary flow following non-homogeneous irradiation of the parotid glands with fractionated radiotherapy have utilised dose-volume his­tograms (DVH's) and various models to assess these relationships. These studies found that the mean dose to the parotid glands is correlated with the reduction of the salivary output [88-90]. The range of the mean doses, which have been found in these studies to cause significant salivary flow reduction, is 26 to 39 Gy [89;90;95]. These calcu­lations, however, have been made with the assumption that the dose on the gland can be averaged disregarding the possibility of regional differences in sensitivity. In the animal model these regional differences do exist [68;96]. Furthermore, also recovery the salivary flow in time has been observed [97]. 
Symptomatic treatment MECHANICAL AND GUSTATORY STIMULATION Natural saliva provides the best protection of the oral tissues [5;41]. Teeth are protected against acidic attacks, both by the salivary buffer systems (mainly bicarbonate) and the pellicle of salivary proteins that is formed on dental enamel. The mucous protein layer on the tooth surface functions as an important diffusion barrier, preventing diffusion of H+-ions to the dental mineral [98]. The salivary proteins, in particular the high molecular mucins, play an important role in the moistening and lubrication of the mucosa! surfaces [5]. Salivary anti-microbial systems, including antimicrobial proteins and peptides, e.g. lactoferrin, histatins and cystatins, play an important role in control­ling the oral microbial ecosystem [5]. Thus, if the salivary glands can still be stimulated to some degree after the radiotherapy, it is highly recommended to use this residual secretory capacity. This can be done by mechanical or gustatory stimulation (Table 1) 
[41;42]. For patients with dry mouth several chewing gums and sucking tablets have been developed. These gums and tablets contain anti-microbial enzyme systems to reduce oral infections and to enhance mouth wetting, or buffer systems to compensate dietary acids. It often is advised to stimulate the salivary flow by sucking on vitamin C (ascorbinic acid). Vitamin C it self is not a salivary stimulant, but a reducing agent that is able to break disulfide linkages between cysteine residues in polypeptide chains. Disruption of these bonds in salivary mucins results in a decrease in the viscosity of saliva. To overcome the rather bitter-acidic taste of vitamin C, usually citric acid and a sweetener like sorbitol are added to commercially available vitamin C preparations. Actually, the additive citric acid results in the increase of salivary secretion. Because of its erosive effects on dental enamel frequent usage of citric acid is not recommended 
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Stimulant Effect Benefit Disadvantage 
Chewing gum Thin-watery saliva More volume Only dentate subjects, 
unless a non sticky 
gum base is used 
Mild taste Too strong taste 
Sucking ointment Longer time Mild taste Foamy saliva 
Taste: menthol Mucous saliva All glands Too strong taste 
stimulated 
sweet Mucous saliva Cheap Cariogenic 
acid Watery saliva Large volume Erosive 
Vitamin C Chemical Reduces Erosive 
reduction viscosity 
TABLE 1 Mechanical and gustatory stimuli.1• 42 
Phannacon Activity Remarks 
Pilocarpine Aselective muscarinic agonist Sweating, nausea, 
half-life 50 minutes 
Bethanechol M3 muscarinic agonist Unhydrolysable 
Carbachol M3 muscarinic agonist Unhydrolysable 
Cevimeline M1 and M3 selectivity Half-life 3 to 4 hours 
Physostigmine Cholinesterase inhibitor Toxic 
Anethole trithione Choleretic 
Bromhexine Mucolytic agent 
TABLE 2 Pharmacological stimuli. • ,42 
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in dentulous patients. The added sweetener makes the use of the vitamin C prepara­tions more palatable. PHARMACOLOGICAL STIMULATION Salivary secretion can also be induced by pharmacological drugs that mimic natural neurotransmitters, particularly those of the parasympathetic nervous system that evoke a rapid secretion of a high volume of watery saliva (Table 2). Pilocarpine (Salagen®) is well known of its largely parasympathetic stimulation. It is not toxic and usually exerts acceptable side effects when used in low dosages of 2.5-5 mg up to 4 administrations per day. The duration of its effect on salivary secretion lasts for only a few hours, because its half-life time is about 50 minutes. Furthermore, it often requires two months or longer reaching its maximal effect. In large sialogogue studies the positive effect of sialogogue treatment for postoperative salivary function loss has been proven [8;99-106].Administra­tion of pilocarpine or other pure cholinergic sialogogues (i.e. carbachol, bethanechol and cevimeline) to stimulate any residual function of the salivary gland post-radiother­apy is worthwhile to a limited extent because the functional gain ceases as soon as the administration of the sialogogue is stopped. This treatment therefore has a limited effi­cacy and is not a definite solution to the xerostomia-related problems. Cevimeline has become more prescribed in the last few years in both the USA and in Japan, but is not yet available in European countries [107-110]. It is a muscarinic ago­nist binding selectively to both M1 and M3 muscarinic cholinergic receptors, just like pilocarpine. Cevimeline has minimal adverse effects on organs like lung and heart. Because it has a half-life of several hours, the stimulating effect on the saliva secretion will last for about six hours. ACUPUNCTURE TO INCREASE SALIVARY SECRETION If saliva secretion can still be stimulated, acupuncture has been reported to result in some relief of the dryness related complaints. Amongst others their are some indica­tions that it may improve salivary secretion in irradiated head and neck cancer patients [ 1 1 1-115] .  SUPPORTIVE THERAPY When the function of the salivary glands is virtually completely destroyed, stimulatory measures will have no effects. In these cases some relief can be obtained by wetting the oral tissues with home-made or commercially available products, including special tooth pastes, oral gels, mouthrinses and saliva substitutes (Table 3). A number of dentifrices are well tolerated by patients with dry mouth, including those of Biotene� and Zendium®. These products contain antimicrobial proteins and have a mild taste. They do not contain a detergent. Usually dentifrices contain deter-























Porcine gastric mucin 
Xanthan gum 
TAB LE 3 Mouthrinses and saliva substitutes.1 , 42 
26 1 CHAPTER 2 
gents as sodium lauryl sulphate making them less suited for patients with dry mouth, because they can be too harsh for the frail mucosal surfaces. Moreover, the taste of many common dentifrices is much too strong for dry mouth patients. Also a number of saliva substitutes with moistening and lubricating properties have been developed for use in xerostomia patients. These substitutes are primarily meant to provide prolonged wetting of oral tissues. The polymer often used as thickening agents in these products is based on carboxymethylcellulose, e.g. in Glandosane®, Xerolube®, Orex® and Saliment® [116;117], natural mucins, e.g. in Saliva Orthana® [7;118-120] or the natural biopolymer xanthan gum, e.g. in Xialine® [121-123]. Mucins or xanthan gum are added to simulate not only the wetting, but also to mimic the visco-elastic properties of natural saliva. Furthermore, saliva substitutes with more gel-like properties have been introduced, such as BioXtra® and Oral Balance®. Gel-like substitutes are preferred by patients during the night and when daily activities are at a low level [124]. Currently, research is ongoing aimed at developing saliva substitutes that besides wetting and lubrication provide protection against micro-organisms. Potential agents to add are derivatives of histatins. Histatins are relatively small salivary antimicrobial peptides, which exhibit a broad spectrum of activity against bacteria and fungi. Some derivatives are even more active [125]. Because of their small size, production costs by chemical synthesis are relatively low, which brings clinical application commercially into reach. E.g. it has been demonstrated that a cationic antimicrobial peptide retains 
in vitro its antifungicidal activity in Xialine® [122;126]. In an experimental, clinical trial the efficacy of a mouthrinse containing P113, a histatin derivative, has been evaluated 
[127]. P113, having activity against a broad spectrum of micro-organisms, decreases experimental gingivitis, plaque and gingival bleeding [127;128]. Based on the literature the following recommendations for the treatment of hypo sali­vation have been proposed [124]. ■ Severe hyposalivation A saliva substitute with gel-like properties should be used during the night and when daily activities are at a low level. During the day, a saliva substitute with properties resembling the viscoelasticity of natural saliva, such as substitutes which have xanthan gum and mucin (particularly bovine submandibular mucin) as a base should be applied. ■ Moderate hyposalivation If gustatory or pharmacological stimulation of the resid­ual salivary secretion does not provide sufficient amelioration, saliva substitutes with a rather low viscoelasticity, such as substitutes which have carboxymethylcellu­lose, hydroxypropylmethylcellulose, mucin (porcine gastric mucin), or low concen­trations of xanthan gum as a base are indicated. During the night or other periods of severe oral dryness, the application of a gel is helpful. 
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■ Slight hyposalivation Gustatory or pharmacological stimulation of the residual secretion is the treatment of choice. Little amelioration is to be expected from the use of saliva substitutes. 
Prevention of radiation damage to the salivary glands The most effective intervention for a reduced salivary gland function is its prevention, because once it occurs, treatment of hyposalivation essentially relies upon stimulation of the residual secretory capacity of the salivary glands [5;99;100;129;130] and the use of saliva replacements if the result of stimulation of the residual salivary flow is insuffi­cient [41;42;118;119;121;131]. Therefore prevention of radiation damage to salivary glands is best accomplished by meticulous treatment planning and beam arrangement designed to spare as much of the parotid and submandibular glands as possible [28;30-
35;88-90;92-94;132-135]. Sparing one parotid gland using three-dimensional treatment planning, conformal dose-delivery techniques and IMRT has been shown not only to reduce the radiation-induced impairment of salivary gland function, but also to con­comitantly improve the xerostomia-related quality of life when compared to conven­tional radiotherapy [9;132;136;137]. The implementation of alternative fractionation schedules, like hyperfractionation and accelerated fractionation, to reduce the side effects of radiotherapy on normal tis­sues has also been proposed [138;139], but its effect on salivary gland function and mor­phology is negligible [49;140]. Direct radioprotection by reduction of cellular damage can be achieved by the use of amifostine (a radical scavenger) when systemically administered during radiation treatment. Subjectively, it has been shown that amifostine has a potential to reduce xerostomia during and post radiation treatment. Randomized studies showed objec­tive data on the sparing effect of amifostine on the post radiation level of salivary secre­tion and the subjective symptoms of xerostomia [10;11;13;141-145]. The high cost of amifostine together with the daily intravenous administration amifostine during radiotherapy and its side effects, facing a heavy burden to the patient, withheld the standard use of amifostine in daily practice. Recently positive trials have been pub­lished studying alternative methods like subcutaneous administration of amifostine, for improvement of the patient convenience, with a comparable protective result 
[12;145-151]. In animal experiments reduction of radiation induced loss of salivary function is seen after pre-treatment with pilocarpine. Pilocarpine being a save, cheap and easy to administer drug, would be ideal to use in daily clinical practice for the reduction of radiation-induced hyposalivation. In the human literature a persisting effect of pilo-
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carpine was observed when the administration of pilocarpine was started before radio­therapy, continued during radiotherapy and sometimes continued for three months post-radiotherapy [8;19-23;152;153]. Yet, the sparing effect was observed in only those patients in whom at least a part of the salivary glands were not included in the treat­ment portals. Other studies could not repeat the potential protective effect of pilo­carpine on post-radiation hyposalivation or the dry mouth complaints [154-157]. Furthermore, although in some studies a positive effect of pilocarpine on the patients dry mouth complaints has been claimed, it apparently did not result in significant improvement of the quality of life of these patients [8;23]. At the moment the definite role of pilocarpine treatment during radiotherapy is not yet clear. Randomized clinical studies, also taking dose and volume effects into account, have to establish the thru efficacy of pilocarpine in reducing radiation induced hyposalivation. 
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Chapter 
Optimum dose range for the amelioration of 
long term radiation-induced hyposalivation 
using prophylactic pilocarpine treatment 
FR BURLAGE, JM ROESINK 1 H FAB E R, A VISSINK, ].A. LANGEND IJK,  HH KAMPINGA 
AND RP C O PPES Publised in: Radiother Oncol 2008;86(3):347-353. 
Abstract Background: To determine dose and time dependency of pilocarpine pre-treatment protection from late damage after unilateral irradiation of the rat parotid gland. Methods and material: The right parotid gland of saline (1mg/ml) or pilocarpine (4mg/kg) pre-treated rats was irradiated with 10, 15 and 20 Gy. Saliva was collected from the irradiated and shielded parotid before, 30, 60, 120 and 240 days after irradia­tion. The number of acinar cells/gland was determined 30, 120 and 240 days after irra­diation by histological examination. Results: Pilocarpine pre-treated rats, protection of parotid gland function was seen in the early-intermediate phase (0-120 days) after 15 Gy and in the late phase (>120 days) after 10 and 15 Gy. Although no protection was observed after 20 Gy, a stimula­tory effect of pilocarpine on the non-irradiated gland resulted in a significant increase in total saliva secretion. The increase in function after pilocarpine treatment was paralled by a significant increase in the number of acinar cells in both the irradiated and shielded glands. Conclusions: Pre-irradiation treatment with pilocarpine induces compensatory response, at lower doses, in the irradiated and at higher doses in the non-irradiated gland reducing late damage, due to stimulation of unirradiated or surviving cells to divide. 
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Introduction 
The exposure of salivary gland to irradiation during radiotherapy among patients with 
head and neck cancer often results in hyposalivation [1] .  Hyposalivation is one of the 
major causes for the development of radiation-induced xerostomia ( dry mouth syn­
drome) which has a negative impact on the quality of life of patients [2] . The mecha­
nisms resulting in radiation-induced hyposalivation in rodents are beginning to 
emerge [3],  and have revealed a number of potentially interesting treatment 
approaches to prevent radiation-induced hyposalivation [4] .  Experimentally, the toler­
ance of the rodent parotid gland against ionizing radiation has been successfully 
enhanced using sialogogues [s], radical scavengers (6-9] and recently also with a mem­
brane stabilizing agent [s]. Effective amelioration of the early effects can be achieved 
using prophylactic treatment with sialogogues like pilocarpine [10-12],  a drug that also 
clinically can be applied with mild side-effects [ 4] .  Moreover, the results of a double­
blind randomized, placebo-controlled study suggested that concomitant administra­
tion of pilocarpine during radiotherapy resulted in sparing of late radiation effects on 
parotid gland function in glands radiated with a mean dose above 40 Gy [ 1 3] .  
Despite these promising results, we recently showed in rats that the radioprotec­
tive effects of pilocarpine pretreatment diminish with dose and time after radiation 
when salivary glands are completely within the radiation field [ 1 2] .  However, in the 
clinical setting, full salivary gland irradiation will only occur rarely, in particular 
when radiation techniques that enable significant sparing of the glands, like 3D-con­
formal radiotherapy and IMRT, have been implemented [14 ;1s]  and result in a con­
siderable sparing reduction but not obliteration of side-effects [ 1 6 ; 1 7] .  
Interestingly, it has been hypothesized that increasing the compensatory poten­
tial of the non-damaged gland, at least in part, underlies the early 'radioprotective 
effect' of pilocarpine in case of unilateral radiation [ 1 1 ] .  This suggests that the ability 
of pilocarpine to ameliorate the radiation-induced impairment of the parotid gland 
function may depend on the remaining number of functional cells, and thus to the 
volume of the gland that lies outside the radiation portals and the radiation dose 
[11 ] .  By stimulating muscarinic-acetylcholinergic receptors, pilocarpine seems to 
stimulate functional cells that survived the radiation-insult or that are located out-
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side the radiation portal to compensate for the loss of function of the radiation-dam­aged cells. When the salivary glands are all completely irradiated to a high dose, the number of surviving cells able to compensate, may be to low to induce long lasting protection [12]. The hypothesis that the ability of pilocarpine pretreatment to ameliorate late irradiation-induced hyposalivation depends on the amount of non-damaged cells in the tissue, and thus is dose and volume dependent, was further tested in this study. 
Materials and methods Animals Male, 8-9 weeks old (body weight 260-280 g) albino Wistar rats of strain Hds/Cpb: WU (Harlan CPB, Rijswijk, the Netherlands were used. They were housed in polycarbonate cages (six rats per cage) under a 14:10-h light:dark cycle. The rats were kept in the experimental unit for 1.5 weeks prior to the experiments. Food (RMH-B, Hope Farms, Woerden, the Netherlands) and water were given ad libitum. All experi­ments were performed in agreement with The Netherlands Experiments on Animal Act (1977) and the European Convention for the Protection of Vertebrates Used for Experimental Purposes (Strasbourg, 18.III.1986). Radiation procedure Prior to irradiation all rats were anesthetized by an intraperi­toneal injection of Ketalar 60 mg/kg and Rom pun 2.5 mg/kg. A 6-mm-thick lead shield with a tailor-made portal was positioned so as to permit direct unilateral, right, parotid gland irradiation. Most of the right submandibular/sublingual and the complete left submandibular/sublingual and left parotid region and oral cavity were excluded from the treatment portal [12].  Meanwhile the rest of the body, including the oral cavity, was shielded. This setup prevents other disorders than the ones inflicted on the salivary glands and ensures an optimal nurturing status of the rats post-irradiation. The gland area was irradiated with a single dose of 10, 15, and 20 at 1.5 Gy min-1. The X-ray appa­ratus (Mueller MG 300, Philips, Eindhoven, the Netherlands) was operated at 15 mA, 200 kV (filters 0.5 mm copper, 0.5 mm aluminium; HVL = 1 mm copper). Dose rate was determined in air with a calibrated electrometer and ionization chamber combination (Keithleg 35040 + NE 2571). Treatments One hour prior to irradiation rats were given prophylactic treatments being: 1 Saline (1 mg/ml) and irradiated with a single dose of 10,15 or 20 Gy 2 i.p. 4 mg/kg pilocarpine and irradiated with a single dose of 10,15 or 20 Gy 17 rats per dose treatment group, 8 for function measurement and 9 for morphol­ogy assessment, were used 
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Collection of saliva Saliva samples of both left and right parotid gland were collected separately and simultaneously under isoflurane/O2 anaesthesia by means of miniatur­ized Lashley cups [18]. The cups were placed upon the orifices of both parotid glands. Saliva was collected for 30 min after stimulation with 2 mg. kg-1 pilocarpine (( + )-Pilo­carpine hydrochloride and sodium pentobarbital, Pharmacist University Medical Cen­ter Groningen, The Netherlands) administered subcutaneously (at t = o and t = 15 min). Saliva was collected in pre-weighed ice-cooled plastic tubes 4 days before and 30, 60, 120, 180 and 240 days after irradiation. The total volume of saliva secreted was esti­mated by weight, assuming the specific gravity of saliva to be 1.0 g.cm-3. The saliva flow rate (µl.min-1) was calculated from the collecting time and volume, and expressed as % of the value before irradiation (± SEM). Tissue preparation and observation methods At 30, 120, and 240 days after irradiation 3 rats were prepared for tissue examination. They were anaesthetized with an i. p. injec­tion of pen to barbital ( 60 mg/kg body weight) and exsanguinated, hereafter the right and left parotid gland were taken out carefully and weighed. The tissue was fixed by immersion in 4% formaldehyde/PBS for 24 hours at room temperature. A standard graded alcohol procedure was used to dehydrate the glands. The tissues were embed­ded in Technovit 7100 (Heraeus Kulzer GmbH, Wehrheim, Germany). Sections of 2 µm were cut with a Leitz microtome (Wetzlar type 1212, Germany). The sections were stained with haematoxylin and eosin (H & E). Each gland was individually examined at three different levels with a distance of 100 µm. At each level, five fields with an area of 0.034 mm2 (0.185 mm x 0.185 mm) and at a magnification of 400 x were randomly cho­sen and investigated. In each field the number of acinar cells was scored. Subse­quently, the average was multiplied by the gland weight of that rat and divided by the gland weight of control animals. Thus a value in arbitrary units proportional to the absolute number of acinar cells per gland was obtained. The number of cells for con­trols was set to 100%. The values for the other conditions were expressed as a percent­age (± SEM) of this control. Statistical analysis The changes observed were expressed as a percentage of the pre­treatment. To evaluate early (0-120 days) or late (120-240 days) effects the areas under the curve for 0-120 or 120-240 days respectively, were calculated (Fig 1D) and expressed as the percentage change compared with sham-irradiated non-treated con­trols. The area under the curve was calculated using the percentage of function (flow rate) of number of acinar cells, as the ordinate and the time (days) as the abscissa (Fig. 1). The results are expressed as means ± SEM. The results were analyzed using a Mann-Whitney test. AMELIORATION OF LONG TERM RADIATION-INDUCED HYPOSALIVATION USING PILOCARPINE 1 45 
Results First, we examined the long-term effect of prophylactic pilocarpine treatment on the function of unilaterally irradiated parotid glands. Radiation caused a dose dependent decrease in the irradiated parotid gland flow rate with no recovery of function up to 240 days post-radiation when the dose exceeded 10 Gy (Fig 1A-C). The shielded parotid gland increased in function to an extend expected when the normal growth of the gland is taken into consideration [12;19]. At 15 Gy, pilocarpine provided late protection of the irradiated gland (figure 1B, closed symbols), which differs from our earlier find­ings of a lack of late protection after bilateral irradiation with this dose [12]. In accor­dance with our hypothesis, the shielded gland also showed a gain in flow rate after pilocarpine treatment that was significantly (p<o.05) higher than the gain seen in the shielded gland in animals that were not pre-treated with pilocarpine (figure 1B and C, open symbols). To be able to compare the protective effect of pilocarpine over the different doses for irradiated and shielded glands in time, the area under the curve (AUC) for the sham and pilocarpine treated animals over the first 120 days (early-intermediate phase [12]) and 120-240 days (late phase) after irradiation was determined. By deduction of the sham-treated AUC from the AUC of the pilocarpine treated group, a quantitative esti­mate of the total gain in saliva flow rate could be determined (see Fig 1D for an exam­ple of the 15 Gy group). For the early-intermediate phase (0-120 days), a significant improvement of salivary flow after pilocarpine treatment was only found when the parotid glands were irradiated with 15 Gy (Fig 2A). For the late period, a significant pro­tective effect of pilocarpine was found when they were irradiated with 10 and 15 Gy (Fig 2B). At 20 Gy no significant pilocarpine induced protection was seen anymore (Figure 2AB). This is consistent with the suggested dose dependency of pilocarpine as a 'radioprotective' agent. Stimulatory effects of pilocarpine on the shielded gland were observed when the shielded gland was irradiated with the high dose of 20 Gy for both phases (Figure 2, open bars). This effect is more pronounced at higher doses in the late phase. When the irradiated gland functions better, less compensation of the shielded gland seems to occur. Prophylactic pilocarpine further increases this effect (Fig 1B,C) although functional compensation of shielded glands normally also occurs. When the combined salivary flow is assessed, a clear protective effect on total saliva output is observed for both phases (Fig 2). 
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FIG URE 1A-B Long term effects of prophylactic pilocarpine treatment on salivary flow rate of irradi­
ated (solid symbols) and shielded contralateral (open symbols) parotid glands. A 10 Gy, B 15 Gy, C 20 
Gy, D 15 Gy + AU Cs. Flow rate is depicted as ± S.E.M. of pretreatment values. N=8, * p<o.05, for whole 
curve. 
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10 15 20 FIGURE 2 Dose dependent gain in salivary flow rate due to pilocarpine pretreatment. Filled bars represent irradiated gland, open bars represent shielded glands and shaded bars represent the com­bined gain in salivary flow of the shielded and irradiated glands. Difference between the AUC of the curves of treated and untreated glands and depicted as % of unirradiated controls. N=8, * p<o.05. AMELIORATION OF LONG TERM RADIATION-INDUCED HYPOSALIVATION USING PILOCARPINE 1 49 
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F I G U RE 3 Compensatory response in shielded glands. Number of acinar cells as % of unirradiated 
controls at the time of irradiation. Closed symbols are the irradiated glands, open symbols are 
shielded glands. Acinar cell number is calculated from the amount of acinar cells per high power 
field x irradiated gland weight/control gland weight. N=3 The compensatory responses in the shielded glands induced by pilocarpine suggested that pilocarpine may stimulate resident salivary gland stem cells to divide and to differ­entiate into functional acinar cells. To test this idea, the number of acinar cells per gland was determined at days 30, 120 and 240 after irradiation. Radiation caused a dose and time dependent decrease in number of acinar cells in the irradiated parotid gland being most prominent at 240 days after radiation. At this time point some recovery of the acinar cell number was seen after a single dose of 10 Gy (Figure 3), in agreement with a functional recovery of the gland at this time point. The acinar cell counts in the shielded glands increased in time, consistent with age-related growth of the glands (Figure 3, open symbols). Interestingly, when the animals were irradiated to the contra­lateral with 20 Gy, the number of acinar cells increased significantly (p<o.05) in the shielded gland at an earlier time point (day 30) after radiation. This effect equalled out in time to yield the same numbers at 240 days after all radiation treatments. Like the data on gland function, the area under the curve (AUC) for the sham and pilocarpine treated animals over the first 120 days (early-intermediate phase [12]) and 120-240 days (late phase) after irradiation was determined. By subtraction of the sham-treated AUC from the AUC of the pilocarpine treated group, like the analysis performed for the flow rates, a quantitative estimate of the total gain in acinar cell number was determined. 
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FIGURE 4 Dose dependent gain in acinar cell number due to pilocarpine pretreatment. Filled bars 
represent irradiated gland, open bars represent shielded glands and shaded bars represent the com­
bined gain in salivary flow of the shielded and irradiated glands. Difference between the AUC of the 
curves of treated and untreated glands and depicted as % of unirradiated controls. N=8, * p<o.05. 
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Adding pilocarpine increased the number of acinar cells only significantly in the irradi­ated gland late after irradiation and only after 15 and 20 Gy (Fig 4). Early to intermediate after irradiation, the shielded glands clearly showed an increase in acinar cell number, which was significant only after 20 Gy to the irradiated gland. During the late phase pilo­carpine induced an increase in the number of acinar cells, again being significant after 
20 Gy. The combined number of acinar cells increased at all doses and time points. In general, the gain in number of acinar cells followed the gain in saliva flow rate after pilocarpine treatment. Furthermore, the highest sparing effect of pilocarpine was observed at 15-20 Gy when the cumulative effect of the irradiated and shielded gland yielded the highest total salivary flow and acinar cell number. 
Discussion This study was initiated to investigate the ability of pilocarpine pretreatment to amelio­rate late irradiation-induced hyposalivation and how this depends on the amount of non-damaged cells in irradiated and shielded parotid gland tissue. We showed that a single prophylactic treatment of pilocarpine shortly before irradiation induced a small but significant amelioration of radiation-induced damage to the rat parotid gland. Part of this was due to an extra compensatory response elicited above the normal compensa­tory response of shielded gland. The level of the compensatory response in the shielded gland seems to be related to the amount of damage inflicted to the irradiated gland. Therefore, it seems that the protective effect of pilocarpine is mainly due to the stimulation of non-irreversibly damaged stem cells, either surviving the irradiation insult or laying outside the irradiation field. In earlier studies, it was already suggested that pilocarpine could 'protect' against the early phase of radiation damage to the salivary gland [10-12,20,21]. The current study also showed late 'protection' although pilocarpine pretreatment could not prevent fur­ther deterioration. The mechanism of protection of pilocarpine may be the stimula­tion of compensatory responses by stimulation of surviving tissue stem cells remaining after irradiation or present in shielded glands, as was suggested in previous publications [10; 1 1]. Pilocarpine stimulates the musarinic receptors on salivary gland cells which acti­vate the ERK1/2 signaling, involved in a variety of biological effects like differentiation and proliferation [20). Together with extra nerve input necessary to induce saliva secre­tion from the few cells left, this may induce undamaged stem cells, which reside in the ductal compartment of the salivary gland, to proliferate and differentiate in acinar cells and repopulate the damaged tissues [21]. The capability of such salivary glands stem cells to repair damaged tissue after radiation has been shown by Lombaert et al 
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[22], who suggested that bone marrow derived cells when mobilized and homed to the irradiated salivary gland may secrete factors which induce the remaining stem cells to proliferate and repair to a certain extent tissue damage. Both in animals and humans negative [8;23;24] and positive [5;10;11;25-30] results were obtained when pilocarpine was administrated prophylactic. The relatively small protective effect (Maximal about 20% gains in flow) may explain the contradicting results presented in the literature. Our study seems to confirm the hypothesis that the protective effects of prophylactic pilocarpine are due to stimulation of 'healthy' tissue in and out-side the irradiation field. In a recent paper, the results of a double blind randomised, placebo controlled study in humans showed that pilocarpine pre-treatment was able to ameliorate late damage to the parotid gland in patients treated with radiotherapy for a head and neck tumour [13]. In this study stratification for the volume of the parotid gland receiving > 40 Gy was done before randomisation, to get a wide range in the dose-volume distri­bution in both groups. A significant difference was observed in the group of patients with a mean parotid dose > 40 Gy receiving pilocarpine pre-treatment compared to the placebo group. In the group of patients with a mean dose < 40 Gy, the incidence of late xerostomia was low, so differences between the pilocarpine pre-treatment and the placebo groups were difficult to detect. Apparently, a substantial amount of damage had to be present to observe the effect of pilocarpine given during radiation, indicating that after low dose irradiation pilocarpine was not necessary to induce 'repopulation'. On the other hand the number of patients receiving a mean dose of > 60 Gy was very limited. Above this dose it is not likely to see any protective effect. Indeed in most neg­ative studies more than 50% of the glands were irradiated with 50 Gy [23;24]. In these irradiated parotid glands, probably the number of stem cells that was destroyed has exceeded the critical limit, explaining the loss of the protective effect of pilocarpine given during radiotherapy. In conclusion, when the saliva flow is reduced below a certain threshold, unirradiated cells or cells surviving the radiation insult may be stimulated to divide and yield a com­pensatory response. This compensatory response is of minor clinical importance when there is no need to provide the gland with extra input since there is no severe lack of saliva. In addition, this compensatory response is also clinically negligible when the dose to the parotid gland tissue has exceeded the critical limit for damage to the stem cell compartment to be able to compensate to a relevant level for the func­tional radiation-induced loss of parotid gland function. In between these ranges an optimum dose range must exist where pilocarpine elicits its beneficial effect. Further studies are necessary to establish the exact dose range in humans. 
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Chapter 
Enhanced proliferation of acinar and progenitor 
cells by prophylactic treatment underlies the 
observed amelioration of radiation injury to 
parotid glands 
FR BURLAGE,  H FABER, HH KAMPINGA, J .A. LANGENDIJK, A VISSINK, AND RP C O PPES 
Submitted 
Summary Background: Administration of pilocarpine before irradiation can ameliorate radia­tion-induced hyposalivation. Indirect evidence suggests that this effect may be medi­ated through induction of a compensatory response. In this study this hypothesis is tested directly, by assessing the proliferation of progenitor and secretory cells in irradi­ated and non-irradiated parotid gland tissue. Methods: In a rat model, parotid glands were unilaterally irradiated with a single dose of 15 Gy, 60 minutes after administration of pilocarpine (4.0 mg/kg). Rats were sacrificed for proliferating cell nuclear antigen (PCNA) labelling, assessing the num­ber of proliferating progenitor and secretory cells, before, and 10 hrs, 1, 3, 7, 10, 20 and 30 days after irradiation. Results: A small radiation-induced increase in PCNA expressing cells was observed, both in the acinar (secretory cells) and intercalated duct cell ( containing the progeni­tor cells) compartment. This increment was significantly enhanced in pilocarpine pre­treated glands. In fact, in this group of animals increased proliferation was observed both in the irradiated and the shielded gland. Conclusions: Amelioration of early loss of rat salivary gland function after radia­tion by pilocarpine pre-treatment is, at least in part, due to compensatory mechanisms through increased proliferation of undamaged cells. ss ! CHAPTER 4 
Introduction Although salivary gland tissue is well-differentiated, with a slow (>60 days) tissue turnover time [1], a rapid decline in parotid and submandibular/sublingual salivary flow occurs after radiotherapy [2]. Several animal studies have shown that prophylac­tic treatment with pilocarpine can ameliorate gland function loss after irradiation. This amelioration does not include the very early effects that are observed 24 hours after a single dose of 15 Gy [3], which are thought to be due to loss of function of the acinar cells [4]. Just before cell loss becomes apparent > 10 days after irradiation [5], prophylactic treatment with pilocarpine has been shown to protect against function loss (> 6 days post-irradiation) [5]. The very early membrane related damage [4] is not protected yet by pilocarpine. The improvement of function is only seen in salivary glands irradiated with a single dose > 15 Gy, indicating that a certain level of damage has to be present for the protective effect becomes apparent. At large single doses, above 30 Gy, the protective effect was lost. Interestingly, effects of pilocarpine are not limited to the irradiated gland; also the shielded, contralateral glands show an increase in the salivary flow [6] and secretory cell numbers [Burlage et al accepted RO]. This 'compensatory effect' of pilocarpine is not observed until day 7 post-irradi­ation, when cell loss starts. This effect was speculated to be due to stimulation of pilocarpine on proliferating progenitor cells. However, this hypothesis yet lacks direct experimental evidence. We now directly addressed this hypothesis by analysing the number of proliferating cells in both irradiated and shielded glands of rats that were either irradiated alone or irradiated after prophylactic pre-treatment with pilocarpine. 
Methods and materials Animals Male albino Wistar rats of the strain Hsd/Cpd: WU (Harlan-CPB, Rijswijk, The Netherlands) were used at 9-10 weeks of age. The body weights were 230-25og at the time of purchase of the rats. The animals were kept 2 weeks to acclimatize before irradiation and housed in polycarbonate cages (six rats per cage) having ad 
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libitum access to water and food (RMH-B, Hope Farms, Woerden, The Nether­lands). The lights were on from 06:00 to 20:00 h, the temperature was 22±2 °C and the relative humidity was 55±5 %. All experiments were performed in agreement with the Netherlands Experiments on Animal Act (1977), the European Convention for the protection of Vertebrates Used for Experimental Purposes (Strasbourg, 18.III.1986) and met the standards required by the UKCCCR Guidelines (UKCCCR, 1998). Parotid gland irradiation The rats were irradiated as previously described by Roessink et al, 1999 [6]. Before positioning, the rats were anesthetized with an intra peritoneal injection of Rom pun (xylazine; Bayer AG, Leverkusen, Germany), 0.48 mg/100 g bodyweight; plus Ketalar (S-ketamine, Pfizer BV; Capelle aan de IJs­sel, The Netherlands), 3.25 mg/100 g bodyweight. In order to irradiate only the right parotid gland, a tailor-made radiation portal was designed. This 3-mm-thick lead shield was positioned to permit direct unilateral (right-sided) parotid gland irradia­tion. Most of the right submandibular/sublingual and the complete left sub­mandibular/sublingual and parotid region and oral cavity were excluded from the treatment portal. The parotid gland on the right side was irradiated with a single dose of 15 Gy. The X-ray apparatus (Mueller MG 300, Philips Eindhoven, the Nether­lands) was operated at 15 mA, 200 kV (filters: 0.5 mm copper and 0.5 mm alu­minium: HVL= 1 mm Cu). The treatment distance to the focal spot of the skin was 32.5 cm, leading to a dose rate at the gland of 1.0 Gy min-1 • This dose rate was deter­mined in air with a calibrated electrometer and ionisation chamber combination (Keithley 35040 + NE-2571). The tissue outside the primary beam received less than 1 % of the dose applied. Experimental design Rats were randomly divided in four equal groups of 24 rats. The control group was sham irradiated and treated with or without pilocarpine (4.0 mg/kg body weight), 60 minutes prior to irradiation. The control group was irradiated to the right parotid region with a single dose of 15 Gy, the experimental group received pilo­carpine (4,omg/kg body weight), 60 minutes prior to irradiation. At day zero, after 10 hrs and 1, 3, 7, 10, 20, 30 days after irradiation both in the standard and the experimen­tal group, 3 rats were sacrificed for immunohistochemistry. Immunohistochemistry The rats were anaesthetized with an intraperitoneal injection of sodium pentobarbital (Pharmacist University Medical Center Groningen; 60 mg/kg body weight) and after exsanguination the parotid glands were extirpated. The parotid glands were fixed in 4% formaldehyde in cacodylate buffer ( 0.1 M; pH 7 .4) for 3 hours at room temperature. After dehydration in a graded alcohol series, the glands 
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were embedded in paraffin (Paraclean, Klinipath). Sections (4 µm) were cut on a 
microtome Gung, Heidelberg, Germany). 
PCNA labelling To examine the proliferation, sections were incubated with PCNA anti­
body (Monoclonal Mouse Anti-Proliferating Cell Nuclear Antigen, Clone PC10, Dako­
Cytomation Denmark A/S), a marker for proliferating cells, followed by Peroxidase­
Conjugated Rabbit Anti-Mouse Immunoglobulin (RAMPO, Dako A/S, Denmark, Code 
No. P 0260). The PCNA labelling index was estimated by the point-counting method [7]. 
An eye-piece square grid (17 x 17 µm2) was used with a density of 81 test points. Every 
pair of perpendicular lines determined a test point. At 6oox magnification, for each 
individual cell type the number of labelled nuclei per total ocular grid area (a) was 
related to the number of nuclei of the same cell type coinciding with test points (b) by 
the formula: LI = (a x 81) / b. 
Statistical analysis Per animal, three different histological slides from each gland were 
analysed for PCNA labelling. The labelling index for each gland was calculated as a 
mean ± standard error of the mean (SEM). The data was analysed with a student-T test, 
an alpha level ofp<o.05 was considered to be statistically signifant. All analyses were 
performed using SPSS for WINDOWS (version 11.0; SPSS Inc, Chicago). 
Results 
To test the hypothesis that pilocarpine exerts its effects through induction of prolifera­
tion of acinar (AC) and/or intercalated ductal (ICD) cells, PCNA expression was deter­
mined by immuno-histochemistry in both irradiated (single dose of 15 Gy) and 
shielded parotid glands, (Figure 1). PCNA labelling was observed and quantified in AC 
and ICD cells both of which are able to form new AC cells [8;9]. 
Expression of PCNA in salivary glands from pilocarpine ( data not shown) or sham­
treated non-irradiated animals did not differ from control animals (Figure 1a). After an 
initial reduction in proliferation, irradiation alone (Figure 1b) induced a small but sig­
nificant increase in PCNA labelling of both AC (figure 2) and ICD cells (figure 3) start­
ing 7 days after radiation and peaking around day 20 (Figure 2 and 3, closed 
diamonds). This is consistent with earlier findings [10]. In these animals, no signifi­
cant changes in PCNA labelling were found in the shielded glands (Figure 1c, Figure 2 
and 3, open diamonds). In pilocarpine-treated animals (Figure 1d,e), the increase in 
PCNA labelling of both AC and ICD cells was greatly enhanced in the irradiated gland 
(Figure 2 and 3, closed squares) reaching a peak of 70-80% PCNA positive cells at day 20 
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FIGURE 1 Expression of PCNA in control (a), irradiated - pilocarpine (b), shielded - pilocarpine (c) 
irradiated + pilocarpine ( d) and shielded + pilocarpine ( e) at 20 days after treatment (Magnification 
20ox, PCNA labelled cells are brown, =>,::;Ac, A=ICD). after irradiation. Most strikingly, PCNA labelling also increased in the shielded gland in pilocarpine pre-treated animals (figure 2 and 3, open squares), although this effect was more pronounced for the AC cells (Figure 2) than for the ICD cells (Figure 3). These results directly demonstrate that radiation-induced increases in proliferation of AC and ICD cells are enhanced by pilocarpine pre-treatment. This increase in prolifer­ation is not exclusive for the irradiated fields but in fact extends to stimulation of pro­liferation in the shielded glands. These data thus are completely congruent with our earlier published data [6] on functionality of the salivary glands after radiation that showed functional 'compensatory responses' and consistent with a model whereby pilocarpine ameliorates loss of salivary gland function after radiation by enhancing proliferation of undamaged AC and ICD cells, [6;11]. 
Discussion The hypothesis that the mechanism of protection by prophylactic pilocarpine treatment on radiation-induced loss of parotid secretory function is due to the induction of prolifer­ation of AC and ICD cells was investigated by PCNA labelling. Activation of muscarinic 
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FIG URE 2 Quantification of PCNA labelling of the acinar cells, after a single dose of 15 Gy on the 
right parotid gland and a shielded left parotid gland, with or without pilocarpine pre-treatment. 
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FIGURE 3 Quantification of PCNA labelling of the intercalated duct cells, after a single dose of 1 5  Gy 
on the right parotid gland and a shielded left parotid gland, with or without pilocarpine pre-treat­
ment. The shaded bar indicates the mean PCNA labelling (± 1 SEM) in the non-irradiated control rats. 
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receptors on the cell membrane using agonists, like pilocarpine, has been shown to reduce early functional damage to completely irradiated parotid salivary glands [4]. Fur­thermore, an accelerated compensatory response in the shielded gland is observed (Burlage et al accepted RO), indicating that stimulation of proliferation of the non-dam­aged salivary cells could serve as an explanation for the observed reduction of radiation­induced loss of parotid secretory function. Pilocarpine did indeed induce a compensatory proliferative response in both the irradiated and shielded glands. Also radiation alone can increase cell proliferation [7] and this compensatory effect, thought to serve as an attempt to recover the secretory cells damaged by irradiation, seems to be enhanced by pilocarpine. Indeed, the increased proliferation in the both the AC and ICD compartment coincides with the improvement of saliva flow rates observed after pilocarpine pretreat­ment [5;6]. Furthermore, the increase in proliferation observed in the shielded gland lead­ing to an increased number of AC cells (Burlage et al accepted RO) can account for the increase in the salivary flow rate as observed in the shielded gland from unilateral irradi­ated rats [6]. Likely, stimulation of the cell proliferation, through pilocarpine-induced muscarinic receptor activation and subsequent activation of the MAPK-pathway, known to occur in many epithelial cells [12], is driving this process. Both the acinar cells, through self-replication, and the intercalated cells, through division and differentiation, have been shown to be able to form new acinar cells [1]. As such acinar and progenitor cells that survived the radiation treatment are likely activated to proliferate in an attempt to restore tissue function. In the late phase and at high doses this reduction in radiation­damage subsides, probably due to lack of remaining progenitor cells. In a clinical study [13] investigating the protective role of pilocarpine given during a full course of radiotherapy, protection was only seen in the glands receiving a mean dose of 
> 40 Gy. Thus, apparently a certain level of damage must be present to result in an induction of proliferation. On the other hand, our preclinical data indicate that the protective effect was lost at very high doses, suggesting that a sufficient number of sur­viving progenitor cells has to be present to initiate recovery of the secretory units dam­aged by irradiation. 
Conclusions In this study, the observed induction of proliferation of AC and ICD cells by pilocarpine pre-treatment principally explains the observed enhanced compensatory response in salivary glands. A sufficient number of surviving progenitor cells apparently has to be present to observe a proliferative response relevant to show less functional loss of a parotid gland upon irradiation. 
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Abstract The aim of this study was to estimate the accuracy and reproducibility of citric acid stimulated parotid saliva sampling. In healthy volunteers a strong correlation (r2=0. 79) between flow rates from the left and right parotid gland was observed. In Sjogren's patients this correlation (r2=0.9o) was even stronger. The intra-individual variation in healthy volunteers was 23.3±5.9%. Increasing the number of collections did not reduce this variation significantly. In head-neck cancer patients, in order to estimate whether repeated measurements result in more reliable baseline values for clinical studies, repeated collections did not result in significant reduction of intra-patient variation similar to the results with the healthy volunteers. Thus, notwithstanding the good agreement between left and right flow rates, a high variation in parotid flow rates has to be considered when planning clinical trials evaluating the effect of treatment on salivary gland functioning. 
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Introduction 
A dry mouth is a very distressing symptom that can result in a number of oral prob­
lems including difficulty with chewing, swallowing and speech, chronic irritation of 
the mucosa and early onset of dental caries. There are multiple causes that can lead 
to salivary hypofunction including systemic diseases, medication, chemotherapy 
and radiotherapy [1-4]. There is a wide variation in the amount of saliva in the 
mouth, not only when there is salivary hypo function, but also within healthy indi­
viduals [5-8]. This is related to a number of factors including circadian rhythm [9;10], 
gender [11] and, usually related to the necessity to use medication, to age [11-14]. 
There is very little data in the literature about variations in salivary flow, which 
rule out circadian rhythms, interobserver variation and differences between indi­
viduals. Additionally, most studies monitoring either a disease process or the 
effect of a particular treatment make use of only one single determination of sali­
vary flow rate. This may be insufficient to determine how much saliva is secreted 
in an individual, particularly as there is high intra-individual variability [7;8;15]. 
Ghezzi et al. [15] suggested that a 45% range should be considered a normal sali­
vary flow rate variation, whereas values below 45% of normal levels could be used 
to define e.g. salivary hypo function or disease related changes. All the saliva sam­
ples in that study were collected on the same day and continuous intravenous 
injection was used to avoid volunteers becoming dehydrated. Although their study 
is one of few studies investigating the variation in diurnal stimulated glandular 
salivary flow in an individual, it does not take into account any variation that 
might occur on different days in the same individual, when collecting saliva under 
standardized circumstances. Moreover, their study does not address whether s im­
ilar results would be obtained from patients with salivary dysfunction. Therefore, 
the aim of this study was to estimate the accuracy and reproducibility of parotid 
saliva sampling with Carlson-Crittenden cups. In healthy volunteers the intra-vol­
unteer variation and the effect of increasing the number of collections to reduce 
this variation were assessed. The data obtained from healthy volunteers were veri­
fied against similar data collected from patients with salivary dysfunction. The 
correlation between flow rates of the left and right parotid gland was studied in a 
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group of Sjogren's patients, whilst a group of head-neck cancer patients partici­pated in an assessment of the effect of repeated collections on the reliability of baseline values for clinical studies. 
Materials and methods 
SUBJECTS Volunteers In order to determine the variation in parotid flow rates, samples from both parotid glands were collected in ten healthy volunteers (four men, six women mean age 48±8 years, range 30-60 years) on ten consecutive working days. None of the volunteers was treated or had been treated for any systemic disease (including rheumatoid arthritis and connective tissue disorders), none were pregnant or taking medication (prescription or non-prescription) other than oral contraception. No changes in medication occurred during the study period. Sjogren's patients In order to assess the correlation between left and right parotid flow in disorders affecting all salivary glands, saliva samples were collected from 140 patients with Sjogren's syndrome. The diagnosis of Sjogren's syndrome was based on the american-european classification criteria [16]. In all patients the samples were col­lected during one visit. Head and neck cancer patients In order to assess whether repeated flow measure­ments will result in more reliable base-line values for clinical trials parotid saliva sam­ples from the right and left parotid glands were collected twice in So head-neck cancer patients (patients with salivary gland tumors were not included). In all patients the samples were collected within the two week period before the start of radiation treat­ment. No changes in medication occurred during the study period. 
Parotid Saliva Collection The investigators were familiarized with the sampling technique by the principal investigator prior to initiation of the study. In a group of volunteers not involved in the study, a series of test collections of parotid saliva was performed by the investiga­tors collecting the parotid saliva samples in the various studies. In agreement with the study of Ghezzi et al. [15] no significant differences were found between the investiga­tors for the stimulated parotid flow rates. Having verified that the variation in parotid 
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salivary flow rates was not investigator dependant, one investigator collected the saliva samples for assessing the reliability of repeated parotid saliva collections in healthy volunteers, two other investigators collected the saliva samples in the Sjogren's patients and again two other investigators collected the saliva samples in the head­neck cancer patients. Ninety minutes before the collection the subjects (volunteers and patients) were prohibited from eating, drinking, smoking or carrying out any aspects of oral hygiene. For repeated collections, the collections were always performed at the same time of the day to rule out circadian rhythm effects [17]. The subjects were placed in an upright position in a quiet room. Prior to the placement of the Carlson Crittenden cups [18], the buccal mucosa was dried with gauze. The cups were placed exactly on the exit of Stenson's duct. The lengths of the tubes connecting the cups with the suction pump and the sampling container were standardized, being 100 cm from the suction pump to the cup ( connected to the outer chamber applying a constant level of suction) and being 50 cm from the cup (connected to the inner chamber, the parotid flow is passive and only driven by the gustatory stimulus) to the preweighed sampling container. Sali­vary flow was stimulated with 2 % (w/v) citric acid, applied with a micropipette (50 µL) to both lateral borders of the tongue at 30-second intervals [19]. Subjects were instructed to minimize movements of the tongue as much as possible and to avoid swallowing. Saliva was collected for ten minutes. Subsequently, the tube connecting the inner chamber and sampling container was emptied (flushed with air) into the sampling container to collect the residual saliva in this tube as the fluid in the tube may constitute a sizable proportion of the secretion (in cases of a very low secretion it could even be the entire sample). The volume of the collected saliva was determined by weight, assuming a specific gravity of 1.0 g/mL. 
Statistical Analysis Data were analyzed using Microsoft Excel. Analysis was done using SPSS version 10.0 for Windows (SPSS Incorporated, Chicago, USA). The reliability of multiple measures of parotid flow rate as well as for comparison of flow rates from the left and the right parotid gland were assessed with Pearson correlation tests. Means and standard devia­tions were calculated separately for each subject. The latter data were used to assess the level of intra-individual variation and to assess the effect of increasing the number of collections on magnitude of this intra-individual variation. P<o.05 was accepted as significant in all tests. 
























■ 0,7 <> 
0 
o,6 
• If' <> 
� 0 <> <> <> 0,5 A A 
■•■ • •� 
x �  • 
A 0 0,4 A � ' F €fll 0 






C A A,,1' : � ♦ 
X 
Xx X 
♦ �ct»♦ : X 0,2 





o,o 0,1 0,2 0,3 0,4 0,5 o,6 0,7 















a. •• • 0 • • 
o o Cb 
♦ � 
♦ CD ♦  
+ i0 � 0 0  O
o 
� <o 400 •• 
0 
0,1 0,2 0,3 
• 0 0 




0,4 0,5 o,6 0,7 
Right parotid flow rate (ml/min.gland) 
Volunteer no. 
0 1 
• 2  
A 3 
• 4  
<> c 5  
■ 6 
<> 7  
R2 o.79 • 8  
X 9 
+ 10 
o,8 o,g 1,0 
Investigator no. 
• 1  
0 2 
R2 o.go 
o,8 o,g 1,0 
FIGURE 1 Correlation between flow rates from the left and right parotid glands. Each point depicts 
the flow rate from the left and right parotid glands in a particular subject at a particular day. Note the 
clustering of the flow rates for the lower secretion rates, while there is a wider spread in flow rates 
measured in subjects with higher flow rates, and the good agreement between the investigators. (A) 
Healthy volunteers, (B)Sjogren patients (investigator 1: white marks, r2:::o.88; investigator 2: black 
marks , r2:::o.92). 
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Results The overall mean stimulated parotid flow rate measured in healthy subjects was o.33±0.13mL/min and o.33±0.14mL/min for the left and right parotid gland, respec­tively. A high correlation was observed between flow rates from the left and right parotid glands flow (r2=0.79, p<o.001, Fig. 1A). The Pearson correlation coefficients for the test-retest reliability of the flow rates from the left and right parotid glands were o.66 and 0.63, respectively. The variation in flow rates between the various measuring points was least pronounced for the lowest flow rates (Fig. 1A). In Sjogren patients an even higher correlation between left-right flow rates was observed (r2=0.90, p<o.001, Fig. 1B). While there was a considerable amount of variation in flow rates among subjects (Fig. 2A), for the pooled data the mean flow rate and variation appeared to be consis­tent for measurements on consecutive days in volunteers (Fig. 2B) and for the two col­lections in two weeks in head and neck cancer patients (Fig. 2C). The standard deviation per person over multiple collection per gland increased with flow rate (Fig. 3A, 3B), but the proportion of flow rate and standard deviation did not significantly increase with increasing flow rates (p>o.05). The intra-volunteer variation in parotid flow rate was 23.3±5.9% (range 7.0-32.3 %). Figure 4 shows the effect of increasing the number of saliva collections on the devia­tion of the mean flow rate from the mean parotid flow rate calculated for up to ten subsequent collections in the same healthy volunteers. As the figures for the left and right gland were comparable, only overall data are shown. From the graph it can be deduced that increasing the number of collections before the start of an experiment did not result in a relevant reduction of the intra-volunteer variation and thus did not lead to a more reliable baseline value for prospective studies on disease progression or treatment evaluation. Similarly, in head-neck cancer patients doubling the number of samples per patient resulted in a negligible reduction of intra-volunteer variation (Fig. 2C). 
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A Mean flow rate of the left and right parotid glands per subject measured on ten consecutive days. 
Note the rather large standard deviations indicating the considerable amount of variation in flow 
rates measured on consecutive days. 
B Variability in flow rates collected on en consecutive working days in ten healthy subjects. Each 
time point and error bar represents the pooled mean and pooled standard deviations. 
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FIGURE 4 Effect of increasing the number of saliva collections on the deviation of the flow rate from the mean flow rate in healthy volunteers. (a) Effect on standard deviation, (b) Effect on measuring error. 
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Discussion The aim of this investigation was to determine the variation in parotid flow rate for repeated collections, to assess the left-right correlation between parotid flow rates and to assess whether repeated flow measurements resulted in better baseline values for clinical trials. The results from this and other studies [5;6;9;10;13-15;20;21] demon­strate that salivary flow rates are not constant and exhibit a considerable amount of variability. The study showed not only the expected large degree of similarity between flow rates of the left and right parotid gland in healthy subjects but also the same degree of similarity in flow rates were seen in patients with Sjogren's syndrome. This was not totally unexpected as in Sjogren's syndrome comparable glands are affected simultaneously. Comparable large similarities had also been reported between left­right parotid flow rates in healthy and drooling children [22;23]. This confirms our view that significant left-right differences occur only in cases of local exacerbation of a disease. Furthermore increasing the number of collections has been shown to have a negli­gible effect on increasing the reliability of base-line parotid flow rates for clinical tri­als. This was not only shown in healthy volunteers, but also in head-neck cancer patients. Although in the latter patients there was a wider variation between flow rates of the right and left parotid glands, the pooled secretions per gland did not show a wider variation than in the healthy subjects. Again comparable observations were made in healthy and drooling children [22;23]. The broad range of stimulated parotid flow rates among healthy subjects observed in this study is comparable with that observed in other studies where varia­tions in stimulated output exceeded 50% [7;8;15]. The stimulated parotid flow rates of individual subjects over a period of two weeks demonstrated a 7-32 % variation over time, with an average variation of 24 %, which is in the lower range [15;24]. Although carefully instructed to minimize oral movements, part of the variation in flow rates might be due to instinctive movements of the tongue and swallowing during saliva collection. The flow rate of citric acid stimulated parotid saliva reported in this study was com­parable with that in recent studies by Fischer and Ship [13], Ghezzi et al. [15] and Ghezzi and Ship [14] and simultaneously much lower than that reported in older studies 
[10;25]. Bartlow et al. [24] even reported acid stimulated parotid flow rates that were lower than those measured by the Ship group and this study (see also Fig. 3B). There is no good explanation for this phenomenon other than the higher frequency of applica­tion of the stimulus in the older studies. Ghezzi et al. [15] demonstrated that the establishment of a standard endpoint must consider the variation present both within each individual and between various indi-
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viduals over time. They suggested a 45% decrease in stimulated parotid flow from 'nor­mal' levels be considered as an objective measure of salivary hypofunction. In our study the greatest amount of intra-subject variation was 32.3% (mean 24%) indicating that the variation in normal stimulated parotid flow levels is probably somewhat lower. Bardow et al. [24] also reported a lower variation in flow rate in healthy subjects (mean 
22%). Therefore, we suggest that it is more appropriate that an increase in the order one quarter to one third of the parotid flow rate from the baseline level of a particular patient should be used as an objective measure to evaluate a 'real' effect of a given therapy in e.g. dry mouth patients, this in addition to subjective assessments of such an effect. Moreover, as increasing the number of initial collections has only a negligi­ble effect on the reliability of the baseline value and is of less a magnitude than the standard deviation of repeated collections, the standard deviation will be the deter­mining factor in calculating the number of subjects to be included in a clinical trial. This is in line with the observations ofJongerius et al. [22] and Rotteveel et al. [23]. Based on our data we would like to suggest that one reliable baseline sample, i.e. a sample collected without any interference due to the technique applied, is sufficient for clinical studies evaluating the progression of a disease or the effect of a therapy. In healthy subjects and patients suffering from Sjogren's syndrome, comparison of left­right flow rates might serve as an intra-individual control. Thus in case of a large dis­crepancy between flow rates of the right and left parotid gland one has to consider that the saliva collection of at least on the glands might be inadequate unless there is a good reason for such a discrepancy, e.g. in case of a unilateral exacerbation of a parotid gland sialadenitis . From this study it can be concluded that large standard deviations (approximately 
24%) for stimulated parotid flow rate have to be taken into account when studies are planned to evaluate the effect of a particular condition on parotid flow rate. This is because disease related changes in salivary flow rate or the effect of a certain treatment has to cross the threshold of the sampling method before these changes can be ascribed to that disease or treatment. The same reasoning applies to studies applying collection of whole saliva or glandular saliva from other sources. Finally, increasing the number of collections has a negligible effect on the reliability of pooled baseline values for clinical studies. 
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Chapter 
Parotid and submandibular/sublingual 
salivary flow during high dose radiotherapy 
F .R. BURLAGE,  R.P. COPPES ,  H.  MEERTENS, M.A. STOKMAN, A. VISSINK. Published in: Radiother Oncol 2001;61(3):271-274. 
Abstract It was studied whether differences in acute radiosensitivity exist between parotid and submandibular/sublingual glands. The results revealed that salivary flow rates decreased dramatically during the first two weeks of radiotherapy. Neither recovery nor significant differences were observed between the production of saliva from the parotid and submandibular/sublingual glands during the 13 weeks observation period. 
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Introduction The head and neck region is a complex region composed of several dissimilar struc­tures, each having a unique response to irradiation: mucosal linings, skin coverings, subcutaneous connective tissue, salivary gland tissue, teeth, and bone/cartilage. Acute changes produced by radiation therapy are observed in the oral mucosa (ery­thema, pseudomembrane-covered ulceration), salivary glands (hyposalivation, changed salivary composition), taste buds (decreased acuity), and skin (erythema, desquamation). The reduction of salivary flow rate and changed salivary composi­tion may result in severe, clinically very distressing complications like oral dryness, impeded oral functioning, nocturnal oral discomfort, burning mouth, and an increased susceptibility to oral infections and dental caries [1-3]. As a result the patients' social activities and quality of life are significantly reduced [4]. Applying precise techniques for calculating the dose-volume relationships, the tolerance dose for complete parotid (PAR) gland irradiation was recently reported to be about 26 Gy [5]. When parts of the gland were spared a higher tolerance was observed [6;7], explaining why higher tolerance doses for PAR gland tissue have been suggested in the past [3;8-14]. In latter studies a rougher estimate of the dose to and volume of the irradiated salivary gland tissue was used. Shannon et al. [15] showed that reduction of secretion from the PAR gland is already measurable after a single dose of 2 Gy whereas no early data are available on the response of the submandibu­lar/sublingual (SM/SL) glands. Obtaining insight in the early effects on SM/SL gland function is of importance as the SM/SL glands are the main source of saliva in rest and during periods with minimal stimulation [16]. The fact that most patients already complain about oral dryness soon after start of radiotherapy [2] assumes an immediate reduction of the SM/SL secretion upon the start of fractionated radiotherapy, although the SM/SL glands have been suggested to be far less sensitive than the PAR glands [17-19]. We, therefore prospectively studied the changes during radiotherapy in salivary secretion of both the PAR and SM/SL glands. 
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Materials and methods PATI ENTS Patients with a head and neck tumour ( excluding parotid tumours) treated by radio­therapy and in whom at least 7 5 % of the volume of both the PAR and SM/SL salivary glands would be included in the treatment portals, were considered to be included in this prospective study. Patients had to be older than 18 years, and should not be suffer­ing from pre-radiotherapy functional impairment of the salivary glands nor using medication that could influence saliva secretion. For preventive mouth care during and after radiotherapy all patients were enrolled to a preventive protocol [20]. Informed consent was obtained from all patients. The study was approved by the ethical commit­tee. In total, 18 patients were included in this study. RADIOTHERAPEUTIC TREATMENT All patients suffered from a squamous cell carcinoma in the head and neck region. Patients were treated either by radiotherapy or by a combination of surgery and post­operative radiotherapy. All patients were treated with a comparable fractionation scheme of one fraction per day, 2 Gy per fraction, 5 fractions a week. The minimal elective dose to the regional lymphnodes was 46 Gy. All patients received a boost to the primary tumour site and the involved lymphnodes to a total dose of 60-70 Gy (Table I). The patients were subjected to a CT-scan for treatment planning (3 mm slices), and for calculating the dose-volume characteristics of the salivary glands. CT-scanning was performed in the treatment position by immobilizing patients in a supine position using a thermoplastic facial mask. The scans always included the tar­get area, the regional lymphnodes, and the parotid and submandibular salivary glands. Treatment plans were more or less standard plans, being two lateral opposed fields and an anterior-posterior field for the low jugular and the supraclavicular lym­phnodes. When possible, individual blockings were used to spare as much normal tissue as possible. Dose calculations were performed on basis of the CT-scan informa­tion using a radiotherapy dose planning system (Treatment Management System­TMS, version 3.0, Helax AB, Upsala, Sweden). The target area and the salivary glands were outlined in each relevant CT-section and a dose homogeneity of ± 5% of the pre­scribed dose within the target area was aimed for. Blocks were designed by using the Beams Eye View facility, with a margin of 8 mm between the blocks edge and the tar­get area. At the end of the treatment, all treatment plans (primary plans and the boosts) were added and the total physical dose values to the salivary glands were cal­culated. 
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SIALOMETRY PAR and SM/SL saliva samples were collected before and 1, 2 1 3,  5 and 13 weeks after start of radiotherapy. It was decided not to collect saliva samples 7 weeks after start of radiotherapy as collection of glandular saliva is often very painful at this time point due to severe mucositis. Latter would result in many missing data. The 5% (w/v) citric acid-stimulated PAR saliva samples were collected using Lashley cups [24). No oral stimulus was permitted 90 min before saliva collection and all samples were collected between 10.00 and 12.00 a.m. Every 30 seconds citric acid was applied with a cotton bud on the lateral sides of the tongue. During a 10 minute period, all saliva samples were collected in preweighed cups. The SM/SL saliva samples were collected simulta­neously with gentle suction from the anterior region of the floor of the mouth using a micropipette. If no salivary flow was observed within 10 min, that measure was assumed to be zero. 
STATISTICS Flow rates after start of radiotherapy were depicted as a percentage of the pre-irradia­tion values. A paired student t test was applied to analyse the changes observed in PAR or SM/SL flow rates. The Wilcoxon-log rank test was used to analyse differences between the PAR and SM/SL flow rates. 
Results In the first two weeks of the radiotherapy a steep reduction in the flow rate of both the PAR and the SM/SL glands was observed (p<o.01, paired t test). After two weeks of radiotherapy with a total cumulative dose of 20 Gy, the flow rate of both gland types has dropped to 20 % of its original flow (Figure 1). Both volume of irradiated gland tis­sue and doses were comparable between the PAR and the SM/SL. At three, five and 13 weeks the flow rate of the SM/SL glands tended to be somewhat higher than the flow of the PAR gland, this tendency was not significant (p>o.05, Wilcoxon log rank test) From six weeks after radiotherapy no further loss or recovery in flow rate of both glands was observed. 
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Patient Age Sex primary tumor stage Total PAR right PAR left SM/SL 
no dose gland gland gland 
volume volume volume 
42 M oropharynx T2 N1 70 Gy 100 % 100 % 100 % 
2 45 M oral cavity T3 N1 6o Gy n.e. n.e. go % 
3 55 F oropharynx T1 No 70 Gy 98 % 100 % 100 % 
4 67 F oropharynx T2 N1 70 Gy 94 % 100 % 100 % 
5 60 M oropharynx T4 N1 60 Gy 98 % 95 % 100 % 
6 Bo M larynx T4 N2b 64 Gy n.e. 76 % 100 % 
7 65 F oral cavity T4 No 6o Gy 83 % n.e. 1 00 % 
8 48 M unkown primary Tx N2b 64 Gy 100 % 100 % 100 % 
9 63 M hypopharynx T2 N2b 64 Gy 95 % 97 % 100 % 
10 56 M oropharynx T4 N2b 64 Gy 100 % 100 % 100 % 
11 52 M oral cavity T4 N2a 6o Gy n.e. 81 % 100 % 
12 62 F larynx T4 N2b 64 Gy 76 % n.e. 1 00 % 
13 60 M oropharynx T2 N2b 64 Gy 100 % 96 % 100 % 
14 52 F oral cavity T2 N2c 64 Gy n.e. n.e. 1 00 % 
15 59 M oral cavity T2 N3 70 Gy n.e. 89 % 100 % 
16 60 M oral cavity T3 N2b 64 Gy n.e. n.e. 1 00 % 
17  42 F oral cavity T3 No 6o Gy n.e. n.e. 1 00 % 
18 48 M oropharynx T3 N3 70 Gy 100 % 100 % 100 % 
TABLE 1 Patient characteristics regarding age, sex, primary tumor, staging and total dose. The mini­
mum dose to salivary gland tissue had to be 40 Gy and at least 75% of the salivary gland had to receive 
that dose for that salivary gland to become included in this study. Otherwise the flow rates from that 
particular salivary gland were not evaluated ( n.e.). 
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FIG URE 1 Par and SM/SL flow rate as a function of time after start of radiotherapy showing a signifi­cant drop of flow rate already 1 week after start of radiotherapy (p<o.01, paired t test). The 1, 2, 3 and 
s weeks time points represent during radiotherapy flow rates and the 13 weeks time point the flow rate on the first follow up. Mean values ± SEM are given (circles: PAR; square: SM/SL). At none of the time points there was a significant difference between PAR and SM/SL flow rates (p>o.05, Wilcoxon· log rank test) . 
Discussion During the period of fractionated radiotherapy no significant difference was observed between the functional response of the PAR (serous), and the SM (seromucous) / SL (mucous) glands on exposure to ionizing irradiation. In the first two weeks of radio­therapy most of the damage has already become manifest; as an 80% reduction in flow rate is observed, regardless of the type of gland. In literature it has been sug­gested, however, that SM/SL glands are more resistant to radiotherapy [17;19]. After single doses of irradiation serous acini (PAR/SM) showed vacuolar degeneration, while mucous acini (SM/SL) showed no acute histophathologic changes [17]. This apparent contradiction between early irradiation-related changes in salivary gland histopathology and function also has been observed in animal studies [21]. Latter authors showed that early changes in salivary gland function can be observed before major histopathologic changes occur and that functional changes persist after the histopathologic changes seem to have virtually returned to normal. In other words, histological evaluations are not a reliable measure for early radiation-induced salivary 
VARIABILITY OF HUMAN PAROTID SALIVA COLLECTION 1 89 
gland damage, whereas the late histopathologic changes (acinar atrophy and chronic inflammation) and the late functional response are comparable between the PAR and SM/SL glands [11). Clinical data investigating the difference in radiosensitivity between the PAR and SM/SL glands are limited. Moreover, to the best of our knowledge no studies on the early response of the SM/SL glands on exposure to ionising irradiation have been reported in the literature. The most valuable study comes from Valdez and co-workers 
[11] who compared patients who were irradiated to various doses and volumes of the PAR and the SM/SL glands. These authors reported no differences in intermediate and late functional loss of both the PAR and SM/SL glands. Similar results have been reported from the retrospective study of Liu and co-workers [9]. Our comparative study extends these findings to show that also during and early after radiotherapy the responses in terms of gland function are comparable between PAR en SM/SL. Increas­ing the number of patients analysed may lead to a significant difference between both groups. This difference will be small and therefore not clinically relevant, however. In agreement with this, also in animal studies no difference in radiosensitivity between PAR and SM/SL glands could be found neither in the rate nor in the extent of the loss of gland function [21-25]. The higher acute tolerance of the SM/SL glands to radiation has become question­able because in this study no difference in acute radiation response between PAR and SM/SL glands could be found. Recently the tolerance dose of the PAR gland to irradia­tion (whole gland irradiated) was calculated to be 26 Gy [5]. In our study an almost complete reduction in flow rate is already observed at a cumulative dose of 20 Gy. Whether recovery after this dose to more than 7 5 % of the glandular volume is still pos­sible, is not known. Since the acute response in the glands is similar it could mean that the tolerance dose of the SM/SL glands is comparable to the tolerance dose of the PAR. In conclusion, this study did not show SM/SL glands are more resistant to radio­therapy than PAR glands. Considering the important function of the SM/SL glands in salivary flow at rest and periods with minimal stimulation, an extra effort in sparing these glands may be very worthwhile, and probably is parallel by an increase of the quality of life after radiotherapy of head and neck tumours. 
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Chapter 
Protection of salivary function by concomitant 
pilocarpine during radiotherapy; a double-blind 
randomized, placebo controlled study 
F.R. BURLAG E ,  J.M. ROESINK 1 H. H. KAMPINGA, R. P.  COPPES, CH. TERHAARD, 
].  A .  LANGENDIJK, PETER VAN LUIJK, M. A .  STOKMAN 1 A. VISSINK. 
Published in: IntJ Radiat Oncol Biol Phys 2007; 70(1): 14-22. 
Abstract Purpose: To investigate the effect of concomitant administration of pilocarpine during radiotherapy for head-and-neck squamous cell carcinoma (HNSCC) on postradiother­apy xerostomia. Methods and Materials: A prospective, double blind, placebo-controlled random­ized trial including 170 patients with HNSCC, was executed to study the protective effect of pilocarpine on radiotherapy induced parotid gland dysfunction. The primary objective endpoint was parotid flow rate complication probability (PFCP) scored 6 weeks, 6 months and 12 months after radiotherapy. Secondary endpoints included LENT SOMA and patient-rated xerostomia scores. For all parotid glands, dose-volume histograms were assessed as the dose distribution in the parotid glands is considered the most important prognostic factor with regard to radiation-induced salivary dys­function. Results: Although no significant differences in PFCP were found for the two treat­ments arms, a significant (p=o.03) reduced loss of parotid flow one year after radio­therapy was observed in those patients which received pilocarpine and a mean parotid dose above 40 Gy. LENT SOMA and patient-rated xerostomia scores showed similar trends towards less dryness-related complaints for the pilocarpine group. Conclusions: Concomitant administration of pilocarpine during radiotherapy did not improve the PFCP, the LENT SOMA and patient-rated xerostomia scores. In a sub­group of patients with a mean dose above 40 Gy, pilocarpine administration results in sparing of the parotid gland function. Therefore, pilocarpine could be provided to patients in whom sufficient sparing of the parotid is not achievable. 
94 1 CHAPTER 7 
Introduction Xerostomia is a common, disturbing side effect among patients treated with radio­therapy for head and neck cancer, leading to considerable morbidity, including severe oral discomfort, problems with speaking, dysphagia, and an increased inci­dence of caries and mucosa! infections [1]. Although salivary gland tissue is a well-dif­ferentiated tissue and theoretically should be relatively radioresistant, studies have shown a rapid decline in parotid and submandibular/sublingual salivary flow, even after low doses of radiotherapy [2]. In human, it has been reported that the TD50 (i.e. the dose to the whole organ leading to a complication probability of 50%) for parotid glands varies from 28.4 Gy [3] to 31 Gy at 6 weeks increasing to 39 Gy at 1 year after completion of radiotherapy [4]. Although new radiation techniques enabled signifi­cant sparing of the parotid glands, the amount of normal salivary gland tissue irradi­ated may still be substantial and result in clinically relevant radiation-induced xerostomia [5-8]. Therefore, protection against radiation-induced salivary gland dam­age may further improve the therapeutic gain. Promising results on reducing radiation injury to salivary gland tissue and thus on preservation of gland function have been claimed by concomitant administration of pilocarpine during radiotherapy. Two non-randomized [9;10], and two randomized trials [11;12] indicated that the risk of radiation-induced xerostomia was reduced when pilocarpine was given during radiotherapy. However, no such beneficial effect was observed in six other randomized clinical trials [13-18]. How can these conflicting results be explained? From animal experiments it is known that the protective effects of prophylactic pilocarpine treatment is dependent on the irradiation dose and irradiated volume of the salivary gland [19]. In the various clinical trials, however, details on dose distribution and dose volume histograms were generally lacking and patients were treated with standard techniques to doses of 50 Gy or more. Detailed information on the dose distribution in the salivary gland is essential as it is the most important prognostic factor for developing salivary dysfunction and therefore potentially the most important confounder. For this reason, it remains difficult to draw definitive conclusions from the results published so far. Therefore, the objective of this prospective randomized placebo-controlled clini-
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cal trial was to investigate the effect of concomitant administration of pilocarpine during radiotherapy for head and neck squamous cell carcinoma (HNSCC) on post­radiotherapy xerostomia. In addition, the observed effects were related to the dose distribution in the parotid glands. 
Materials and methods 
ELIGIBILITY CRITERIA To be eligible for this study, patients had to have a biopsy confirmed HNSCC. All patients were treated at the departments of Radiation Oncology of the University Medical Centre Utrecht and the University Medical Centre Groningen. Eligible patients received either primary or postoperative radiotherapy. The initial 5% (w/v) citric acid stimulated parotid salivary flow had to be > 0.1 ml/min. Excluded were patients that underwent previous irradiation and/or previous or concurrent chemotherapy, patients with salivary gland tumors, patients with severe cardiovascular disease or chronic obstructive pulmonary disease, patients using cardiac medication like /3-blockers (contra-indication for the use of pilocarpine) or other medication influencing salivary gland function. Also, pregnant women were excluded. The study was approved by the local ethical committees of the participating centers and written informed consent was obtained from all patients. 
STUDY DESIGN All patients included received at least 40 Gy to a part of both parotid glands. This threshold dose was chosen at that time, because it was considered a high enough dose to cause definitive damage to the parotid glands. The volume of parotid tissue included in the radiation portals varied, depending on the primary tumor site. To ensure an equal distribution between patients receiving placebo and pilocarpine, patients were stratified into three groups based on the expected irradiated volume of the parotid glands. Both submandibular glands, if not removed as part of a cervical lymph node dissection, always were irradiated to a dose of at least 40 Gy. The three groups had an expected irradiated volume of the parotid gland of 25%-45%, 46%-75% and >75%, respectively. These three volume groups were arbitrarily chosen, as we wanted to be sure that the whole range of irradiated volumes above the tolerance dose would be included in the study. Patients with an expected irradiated parotid vol­ume <25% were excluded from this study as these glands were expected to exhibit an almost normal parotid gland function post radiotherapy. Planning CT-scans were made in all patients for treatment planning and for delineation of organs at risk, including the spinal cord and the major salivary glands. All patients were randomly assigned to receive radiotherapy plus pilocarpine (5 mg 
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tablets, 4 times per day) versus radiotherapy plus placebo (similar tablets, 4 times per day). Pilocarpine or placebo administration was started 2 days before the start of radio­therapy and stopped 14 days after completion of radiotherapy. 
RADIOTHERAPY Radiotherapy was delivered using megavoltage equipment ( 6 MV linear accelerator). The clinical target volume (C'IV) of the initial field encompassed the primary tumor site with a 1.5 cm margin, the neck node levels in which pathological nodes were found and the elective nodal areas on both sides. The C1V of the boost included the primary tumor site plus a 1.0 cm margin and the nodal areas tumor-positive lymph nodes. For the planning target volumes (P'IV), an additional 0.5 cm was applied in all directions. Treatment was given with a conventional fractionation schedule. The ini­tial P1V was treated with daily fractions of 2 Gy to a total dose of 46 Gy. In case of pri­mary radiotherapy, the P1V of the boost was irradiated to a total dose of 70 Gy with a dose per fraction of 2 Gy. In case of postoperative radiotherapy, the P1V of the boost was irradiated to a total dose of 60 to 64 Gy, depending on surgical margins and the presence of lymph node metastases with extranodal spread. 
ASSESSMENT OF SALIVARY SECRETION Assessment of parotid salivary flow was performed, by four experienced investigators, two times before the start of the radiotherapy ( to estimate the baseline value), and 6 weeks, 6 months and 12 months after completion of radiotherapy. Using the Carlson­Crittenden cups saliva from the right and the left parotid gland was simultaneously collected under standardized conditions during 10 minutes [20]. At the same time saliva from the remaining salivary glands (predominantly submandibular/sublingual saliva) was collected with gentle suction using a syringe from the floor of mouths. Sali­vary flow was stimulated with 5% (w/v) citric acid, applied with a micropipette (50µ1) to the lateral border of the tongue at 6os intervals. In addition, the latent period was assessed which was defined as the time elapsed between the start of saliva collection (first administration of citric acid) and start of saliva output (first drop of saliva origi­nating from the orifices of the parotid glands). The collected saliva samples were weighted to estimate the volume (ml) assuming the specific gravity of saliva to be 1 .0 g/cm3• The salivary flow rate (ml/min) was calculated by the formula: flow rate = ml of saliva/ (10 min - latent period). 
ASSESSMENT OF SUBJECTIVE COMPLAINTS At the same time points saliva was collected, patients were asked to complete validated head and neck symptom questionnaire (12 questions) containing domains on xerosto­mia, eating and swallowing complaints. The questions were scored on a 5-point Lick-
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ert-scale and are also used in our clinic by the oral surgeons for patients with Sjogrens syndrome. In addition, the lent soma morbidity scoring system [21] was completed. STATISTICS The primary endpoint was parotid flow rate complication probability (PFCP) defined as a reduction in flow rate to < 25% reference to the flow rate at baseline (19). A PFCP incidence of 60% in the placebo group and of 35% in the pilocarpine group was assumed. To detect this difference, a total number of 162 patients was needed (power 
90%, alpha two-tailed: 0.05). Taking into account a dropout rate of 5% after study entry until the time of primary outcome assessment, a total number of 170 patients were required. The parotid flows of both glands were evaluated separately. The primary endpoint was tested on statistical significance with the chi-squared test. Changes over time of the submandibular/sublingual flow rate, LENT SOMA scores and patient-rated xerostomia scores were evaluated by group-based analyses, comparing changes in mean scores for the two treatment groups at each time point. Differences between the two arms were tested for statistical significance with a repeated measurement AN OVA using a mixed effect modeling procedure. F-tests were used for testing main effects of group and time, and an interaction effect of group ver­sus time. For the evaluation, the intention to treat approach was applied. Logistic regression analyses were performed to study the association between dose-volume parameters (mean dose both parotid glands) and other baseline charac­teristics (sex, age, type of radiotherapy; primary of postoperative) with the PFCP at 6 weeks, 6 months and 12 months after completion of radiotherapy. Associations were expressed as odds ratios (OR). In addition, to investigate whether pilocarpine influ­enced the effect of the mean parotid dose on the PFCP, the presence of an interaction term between mean parotid dose and treatment arm was investigated. All analyses were performed using SPSS for WINDOWS (version 11 .0; SPSS Inc, Chicago). 
Results RANDOMIZATION A total number of 170 patients were included between April, 1999 and October, 2003. The analysis was performed after a minimum follow up period of one year among the patients that were still alive and free of tumor recurrence. One patient refused to take the medication after randomization for unclear reasons and abandoned further partic­ipation. Therefore, this patient was left out the evaluation. Thus, a total number of 169 patients were evaluated, of which 85 patients were assigned to receive pilocarpine and 84 patients to placebo (Figure 1). 
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1 70 patients randomised 
Allocated to placebo (n=85) 
Received allocated intervention (n=84) 
Did not receive allocated intervention (n=1) 
Reason: patient refusal 
Completed medication (n=83) 
Analysed at 6 weeks (n=6g) 
Analysed at 6 months (n=65) 
Analysed at 12 months (n=58) 
FIGURE 1 Trial Profile 
Allocated to pilocarpine (n=85) 
Received allocated intervention (n=85) 
Did not receive allocated intervention (n=o) 
Completed medication (n=84) 
Analysed at 6 weeks (n=72) 
Analysed at 6 months (n=59) 
Analysed at 12 months (n=ss) 
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Placebo (n=84) Pilocarpine (n=85) 
p-value 
Variable Number % Number % 
Sex ns 
Female 13  16% 22 26% 
Male 71 84% 63 74% 
Age ns 
18-60 years 42 50% 50 59% 
>60 years 42 50% 35 41% 
Type of radiation ns 
Primary 43 51% so 59% 
Postoperative 41 49% 35 41% 
T-classification ns 
T1 14  17% 10  1 2% 
T2 41 49% 40 47% 
T3 1 2  14% 17 20% 
T4 14  17% 15 1 8% 
Unknown 3 4% 3 4% 
N-classification ns 
No 41 48% 40 48% 
N+ 43 52% 45 52% 
Submandibular glands removed ns 
None removed 48 57% 52 61% 
One removed 32 38% 31 37% 
Both removed 4 5% 2 2% 
Site ns 
Oral cavity 1 5  18% 13  1 5% 
Oropharynx 13 16% 17 20% 
Larynx 42 50% 43 51% 
Hypopharynx 6 7% 6 7% 
Nasopharynx 4 5% 2 2% 
Unknown primary 3 4D/o 3 4% 
Other 1% 1% 
TAB LE 1 Patient characteristics 
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Randomization was executed by the hospital pharmacist by computer, using random permuted blocks within strata. The randomization key was opened after the last saliva collection, i.e. one year after the last patient was included and after completion of all planned assessments. The patient characteristics are listed in Table 1. The mean dose to the parotid gland in the placebo group was 39.6 Gy (SD 14.9) and 40.9 Gy (SD 14.0) in the pilocarpine group (P=o.42). Patients were well balanced with regard to the other pre-treatment characteristics. 
COMPLIANCE After randomization, 2 patients failed to complete medication treatment for different reasons. One patient (this patient received pilocarpine) terminated the medication because of excessive sweating and the other patient due to a suspected severe side effect (this patient received the placebo). However, the side effects observed in the cur­rent study were very mild. Sweating was the most frequently mentioned side effect and a few patients reported complaints of slight nausea or mild head ache, all being tran­sient. One patient experienced grade 2 toxicity for excessive sweating and none of the patients experienced grade 2 or higher toxicity for nausea, headache or vomiting. The data of both patients were analyzed according to the intention-to-treat principle. 
PAROTID FLOW RATE COMPLICATION PROBABILITY (PFCP) The primary endpoint in this study was the PFCP. The PFCP at the different time points for all parotid glands and for both treatment arms is shown in Figure 2. No sig­nificant differences between pilocarpine and placebo were noted. 
SUBMANDIBULAR/SUBLINGUAL FLOW RATE When compared to baseline values, submandibular/sublingual flow rates were signifi­cantly reduced after radiotherapy. No difference was noted between the pilocarpine and the placebo group and no recovery was observed during follow up. 













6 weeks 6 months 1 2 months 
FIGURE 2 Parotid Flow rate Complication Probability according to treatment arm at different time 










To 6 weeks 6 months 12 months 
Placebo (MPD 0-40 Gy) 
□ Ptlocarpine (MPD 0-40 Gy) 
0 Placebo (MPD > 40 Gy) 
0 Pilocarpine (MPD > 40 Gy) 
FIG URE 3 LENT SOMA score according to treatment arm at different time points, stratified by mean 
parotid dose. No significant difference between placebo and pilocarpine in low dose group (mixed 
model: p=o.40) and high dose group (mixed model: p=o.21). In patients with a MPD > 40 Gy, a statis­
tical significantly lower score at 6 months is obseived. * Significantly different p=o.05. 
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To 6 weeks 6 months 12 months 
■Placebo (MPD 0-40 Gy) 
□Pilocarpine (MPD 0-40 Gy) 
□Placebo (MPD > 40 Gy) 
OPl ocarpine (MPD > 40 Gy) 
FIGURE 4 Patient-rated xerostomia according to treatment arm at different time points after com­
pletion ofradiotherapy, stratified by mean parotid dose (MPD). No significant difference between 
placebo and pilocarpine in low dose group (mixed model: p=o.60) and no significant difference in 
high dose group (mixed model: p=o.17). * Significantly different p=o.017. 
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FIG URE s PFCP as a function of the mean parotid dose in patients that received radiotherapy + 
placebo or patients that received radiotherapy + pilocarpine. With pilocarpine, recovery at 12 
months is significantly more pronounced compared to placebo. 
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Ill Placebo (MPD 0-40 Gy) 
□ Pilocarpine (MPD 0-40 Gy) 
0 Placebo (MPD > 40 Gy) 
0 Pilocarpine (MPD > 40 Gy) 
FIGURE 6 Parotid Flowrate Complication Probability according to treatment arm at different time 
points after radiotherapy, stratified by mean parotid dose. 
Discussion In this prospective randomized placebo-controlled study, we investigated if pilo­carpine, when administered during radiotherapy, could act as a radioprotector for parotid gland function. Overall analysis showed no statistically significant differences between the pilocarpine and the placebo group for the PFCP, the submandibular/sub­lingual flow, the mean LENT SOMA score and the patient-rated xerostomia score. However, the results of an additional explorative analysis, taking into account the influence of the mean dose to the parotid glands, suggested a significant sparing of parotid gland function with pilocarpine observed among patients that received a rela­tively high dose the parotid gland, i.e. a mean parotid dose >40 Gy. Furthermore, in this subset of patients, tendencies towards less patient-rated xerosto­mia and lower LENT SOMA scores were noted when pilocarpine was administered, albeit that these differences were not statistically significant at all time points. It should be noted that there was also a trend towards better sparing at other time points (i.e. 6 weeks and 6 months) but these difference were not statistically significant. 
It is generally accepted that the mean dose to the parotid glands is the most important prognostic factor for xerostomia and thus a potential confounder for the effect of pilo­carpine. Therefore, this variable was used as stratification factor to ensure that the 2 groups were well balanced with regard to the mean dose in the parotid glands. At the 
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time the study started (beginning 1999), the TD 50 for the parotid glands was not yet clear. Therefore, a threshold dose of 40 Gy was chosen, considered sufficiently high to cause definitive damage to the parotid glands. The question arises why concomitant pilocarpine during radiotherapy would only pro­tect the parotid gland function in case the mean dose is > 40 Gy. A similar effect was observed in animal experiment [19] were a protective effect of pilocarpine was only seen after single doses of 15 Gy or more, indicating that a certain level of damage needs to be present before the stimulatmy effects of pilocarpine on the non damaged gland tissue become apparent. This may not be the case in the subset of patients with a mean dose of 0-40 Gy. In our clinical trial, a mean dose of >40 Gy in 2 Gy fractions is likely to represent the dose group in the animal studies of above 15 Gy single dose 
[22;23]. This may result in late damage to a sufficient amount of parotid gland tissue to cause a reduction in salivary flow [3;4], while at the same time, the amount of salivary tissue that receives a dose which does not lead to irreversible damage is clinically rele­vant. It has to be stressed that in our clinical trial, the proportion of patients in which the entire parotid gland tissue received a dose > 60 Gy was very small. Probably, there will be an upper dose limit for the protective effect of pilocarpine, but this would require further subset analysis, which we considered not appropriate. Our findings may have important clinical implications. When the mean parotid dose remains below 40 Gy, either in case of bilateral irradiation with conventional tech­niques or 3D-conformal radiotherapy, the addition of pilocarpine during radiotherapy appears to have no beneficial effect. However, for those patients in which the mean parotid dose cannot be reduced below 40 Gy, pilocarpine given during radiotherapy could result in better outcome of parotid gland function and subsequent patient-rated xerostomia, in particular for the late effects. It has to be emphasized that this study was not designed and powered to investigate the beneficial effect of pilocarpine in two subsets of patients. However, as the compliance of pilocarpine administration was excellent and the side effects were rare and minor, one could argue that patients treated in institutions in which advanced techniques for radiation delivery are not available and/or patients in which even IMRT fails to spare the parotid gland sufficiently, the administration of pilocarpine could be a good alternative to spare parotid function. In the present study, we found a TD50 of 41 Gy among patients that were treated with radiotherapy alone, which is higher than found by others [3;4]. It is difficult to find a clear explanation for these apparently conflicting results. Possibly, the differ­ences can be statistically explained by the fact that in every sample, there is a certain inaccuracy as expressed by the 95%-confidence interval. In this sample, the lower value of the 95% confidence interval was 34 Gy, which is very near the results found by 
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Eisbruch et al. [3], who did, however, not mention a 95%-confidence interval in their publication. In the eight randomized trials reported in the literature assessing the sparing effect of pilocarpine administered concomitantly with radiotherapy on parotid gland function, the dose volume effects were not taken into account [11-18]. Group sizes varied from 43 to 245 patients, only two studies included a substantial number of patients [15;18]. Moreover, in three out of the eight studies, only subjective measurements were obtained. In the five studies not showing any effect of pilocarpine given during radio­therapy, no reliable late data on the salivary flow was obtained. In the large placebo controlled trial by Warde, et al. [15] some information about the minimum dose (> 50 Gy) and the minimum irradiated volume (>50%) was provided. In the latter study, how­ever, no differences were observed between the treatment groups with regard to the sensation of a dry mouth, quality of life and acute toxicity. In the latter trial no data on the parotid salivary flow was available. In the large study by Scarantino et al. [18], both subjective and objective (unstimulated and stimulated salivary flow) measurements were obtained. No significant differences in xerostomia, mucositis and quality of life were found. There was however a statistical increase in the average unstimulated sali­vary flow in the pilocarpine group, whereas no difference was noted in the stimulated parotid salivary flow. To date no studies has reported on the role of the other salivary glands, in particu­lar the submandibular and/or sub lingual glands, in the development of xerostomia. Under resting conditions the submandibular and sublingual glands are the major source contributing to wetting of the oral mucosa, while sparing of parotid gland func­tion need some stimulation to result in a reduced sensation of oral dryness. Recently, Jellema et al. [24] reported on the incidence of patient-rated xerostomia after bilateral irradiation. In that study, both the mean parotid dose as well as the mean sub­mandibular dose was significantly associated with patient-rated xerostomia. More­over, the tolerance dose of the parotid glands for patient-rated xerostomia significantly depended on the mean submandibular dose. This might be a major reason that our and most other studies did not reveal a significant improvement of subjective sensa­tions of a dry mouth. In future studies, more attention should be paid to the role of the submandibular gland in the development of xerostomia. In our study, no protection of pilocarpine on the submandibular and/or sublingual flow was observed; however these glands were radiated with at least 40 Gy or had been removed as part of the dis­section procedure. 
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Conclusions In this double-blind randomized placebo controlled study the role of pilocarpine, 4 times s mg/day, given during radiotherapy for the protection of radiation induced xerostomia, was investigated. Overall, no statistically significant differences between the pilocarpine and the placebo group, for the primary end point PFCP and the sec­ondary endpoints could be found. However, the results of the present study also sug­gested that the beneficial effect of pilocarpine depends on the dose distribution in the parotid glands, indicating that when the mean parotid dose exceeds 40 Gy, pilocarpine significantly spares parotid flow and reduces patient-rated xerostomia in particular after 12 months. Although pilocarpine medication should not be given as a standard treatment for the protection of radiation induced damage to the parotid glands, it could be considered for patients treated in institutions in which advanced techniques for radiation delivery are not available and/or patients in which even with advanced radiation techniques fails to spare the parotid gland sufficiently. 
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Chapter 
Summary and general discussion 




Summary and general discussion Regarding late morbidity, hyposalivation is one of the most frequently reported radia­tion-induced side effects which has a negative impact on health-related quality of life 
[1;2]. Besides the subjective sensation of a dry mouth (xerostomia), saliva also plays a major role in speech, taste perception, mastication, bolus formation, swallowing, rins­ing the mouth, clearing and diluting food detritus and bacterial matter, and mucosa! protection [3;4]. In this thesis we investigated the role and the mechanisms of pilo­carpine treatment during radiotherapy in the prevention and reduction of radiation­induced hyposalivation. The last decades, a lot of effort has been put in the development of new strategies to reduce the loss of salivary gland function after radiotherapy, both in preclinical and clinical research (chapter 2). More detailed information about the patho-physiological mechanisms of the damage to the salivary glands has become available, especially from animal laboratory data. In a rat model, a four-phase pattern both in the sub­mandibular and the parotid gland of the rat could be distinguished [5;6]. The acute phase ( day 0-10) is characterized by a rapid impairment of the water secretion, without substantial cell loss and probably results from a disturbance in the signalling path­ways responsible for the watery secretion of the saliva [7]. In the early phase ( day 10-60 ),  loss of the compromised acinar cells, due to the damage induced to the cell membrane and a lack of compensation by cell proliferation, results in a loss of amylase secretion. During the intermediate phase ( day 60-120 ), no major changes in the cell number and the salivary flow has been observed. The late phase ( day 120-240) is mainly character­ized by a further loss of proliferating of gland cells (progenitor or stem cells), resulting in acinar cell loss and fibrosis of the gland [6-8). This results in a further deterioration of the salivary flow and decrease in amylase production. The conclusion is that two separate mechanisms cause salivary gland dysfunction after irradiation. Initially, there are defects in cellular function because of selective membrane damage and later on, a shortage of functioning secretory cells resulting from the diminishing of stem/progen­itor cells and damage to the cellular environment. When patients are subjected to a full course of fractionated radiotherapy, loss of salivary function already occurs after a relatively low cumulative dose. To evaluate the 
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changes in the salivary flow, both in the parotid and submandibular/sublingual glands, the salivary flow was measured during and after conventional radiotherapy, in a group of patients treated for a head and neck tumour. In this study ( chapter 5) loss of 
>80% of the salivary gland secretory function was observed during the first two weeks of treatment. These results indicate that even below the frequently mentioned and generally accepted tolerance doses (i.e., for the parotid gland a LTD50 of 26-3 1 Gy), a substantial functional loss of salivary flow becomes apparent. This very early loss in salivary gland function is probably reversible and is the result of a disturbed signalling pathway [7]. Moreover, no differences between the parotid and submandibular/sublin­gual glands could be observed during and twelve weeks after radiotherapy, indicating no difference in the radiosensitivity of the major salivary glands. The leading role of secretion from the submandibular, sublingual and minor salivary glands in the dry mouth sensation by patients, is supported by the results of a number of clinical stud­ies, indicating that the radiation dose administered to the submandibular glands and minor salivary glands are also important predictive factors for xerostomia [9-11]. There­fore, in future studies, more attention should be paid to the non-parotid salivary glands [9;11;12]. Reduction of radiation damage to salivary gland tissue can be executed at different levels. Sparing the salivary glands tissue by reducing the radiation dose and/or the irra­diated gland volume, using new radiation techniques, like intensity modulated radio­therapy (IMRT) [13-17] has been shown to reduce radiation-induced hyposalivation and xerostomia. If adequate sparing of the salivary glands by this new radiation technique is not possible, e.g., due to the localisation of the primary tumour, involvement of bilat­eral lymph nodes, and/or the fact that this new technique is not yet available in all radiotherapy departments, the use of potential protective agents remains salient [4]. Protection may be obtained by the use of selective radio-protectors, like the radical scavenger amifostine. Both in clinical randomized trials and in animal studies, ami­fostine has proved its efficacy [18-28]. The main disadvantages of amifostine, however, are the invasive route of administration (intravenous or subcutaneous) daily during radiotherapy, high costs, and its side effects including hypotension, vomiting and allergic reactions [29]. Although amifostine can reduce the incidence of xerostomia with approximately 20-30%, the proportion of patients suffering from xerostomia after radiotherapy combined with amifostine still remains substantial. These disadvan­tages, as well as the assumed tumour protection [30], have prevented the use of amifos­tine on a routine basis in clinical practice. In animal studies, pilocarpine, when given before irradiation of the parotid gland, resulted in reduction of hyposalivation [31;32]. The first non-randomized clinical stud­ies in head and neck patients indeed showed a reduction in xerostomia [33;34], how­ever, larger randomized trails resulted in conflicting results [35-42]. These conflicting 
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results may be explained by the limited number of patients included, the different endpoints used; both objective and/or subjective loss of salivary function, and the lack of variation and exact calculation of the irradiated volume and dose in the studied pop­ulations. In this thesis (see chapter 1), we mainly focussed on the potential role ofpilo­carpine to reduce radiation-induced loss of salivary function. Pilocarpine is a cheap, easy to administer, relatively save drug with mild side effects [43] and could be consid­ered a very reasonable drug to be used in clinical practice, provided that there is suffi­cient evidence regarding its efficacy to reduce radiation induced xerostomia. Both in the rodent model and in a large randomized trial, executed in head and neck cancer patients treated with radiotherapy, the efficacy was tested. In chapter 3, the results of the study in which we investigated the early and late radiation-induced parotid gland function loss in pilocarpine pre-treated rats are described. In the acute phase, pilocarpine-induced activation of muscarinic recep­tors and its second messengers seem to stimulate the proliferation of radiation sur­viving progenitor cells that increase the number of acinar cells, hereby restoring the cell loss resulting in a significant improvement in salivary flow up to 1 20 days after irradiation. For the late phase ( 120-240 days), a partial recovery of salivary flow was observed after a single dose of 10 and 15 Gy, but not at after single doses � 20 Gy. In addition, a stimulatory effect of pilocarpine on the contralateral, shielded parotid gland was found, which was most pronounced at higher doses (20 Gy) and lasted into the late phase. In general, the observed late partial recovery of parotid salivary flow rate after pilocarpine treatment was paralleled by a gain in the number of acinar cells. These findings strongly suggest that after the acute phase, the main effect of pilocarpine is due to stimulation of cell proliferation. This hypothesis was supported by data presented in chapter 4 where an increase in proliferation, as determined by PCNA labelling, of both acinar and intercalated duct cells at day 10 and 20 was observed. From these data we deduced that pilocarpine may probably work within a certain dose/volume range. At lower dose/volume exposure limited damage is expressed and thus no stimulation of pilocarpine is required to restore function. At the highest dose/volume exposures, the damage is too extensive and thus there are no residual, surviving cells that can be stimulated by pilocarpine to proliferate and restore function after the radiation exposure. In other words, protection of pilo­carpine will only be seen, if there are enough surviving progenitor cells left after irra­diation, on which pilocarpine can act to induce cell proliferation to restore cell loss. Therefore, it could be argued that pilocarpine should not be considered as a classical radioprotector, but as a stimulator of cell proliferation of surviving progenitor cells. In the rat model a uniform dose over the whole gland was used, whereas in patients a dose gradient over the salivary glands is more common. Therefore it was vital to eval-
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uate the dose-volume histograms to get more information about the volumes receiving a low dose and thus have more surviving progenitor cells. These surviving cells then can be stimulated to proliferate, by pilocarpine administration. This is why we analysed effects of pilocarpine in a clinical trial in which patients were separated into 3 different dose/volume groups (chapter 7). In the randomized study (chapter 7) the submandibular glands were either removed as part of the neck dissection procedure or were completely included in the high dose area. The primary endpoint in this study was the parotid flow rate compli­cation probability (PFCP), defined as a decrease of the salivary flow less then 25 % reference to the baseline (as commonly used in the literature as the definition of nor­mal tissue complication probability (NTCP) to the salivary glands). Secondary end­points were xerostomia scored with the LENT (Late Effects on Normal Tissue) SOMA (Subjective Objective Management Analytic) score and patient-rated xerostomia score using a questionnaire. No statistical significant differences in the PFCP, the LENT SOMA score and patient-rated xerostomia score were found between the pilo­carpine and the placebo group, when considering the total range of cumulative doses applied in this study. However, in patients receiving a mean dose of >40 Gy to the parotid gland, a difference in the PFCP between the pilocarpine and the placebo group was found, being most pronounced and statistically significant at one year. For the LENT SOMA and the patient-rated xerostomia scores, similar trends were observed. On the contrary, in patients treated with a mean dose :s_40 Gy, no difference between placebo and pilocarpine treatment was found. However, it should be emphasized that the PFCP was already very low in this group (i.e. between 10 and 20 
%), and therefore there was little room for further improvement by pilocarpine. Although this study was not powered for subgroup analysis, these findings suggest that a certain level of damage has to be present before a beneficial effect of pilo­carpine can be expected. These findings from the clinical study are in agreement with those obtained from the previous mentioned animal studies [6;31;32]. On the other hand, if the damage exceeds beyond a certain level, no effect can be expected from concomitant pilocarpine administration, due to the lack of cells able to prolif­erate and restore the damage (see chapter 3). In the larger randomized clinical studies that were published in the medical liter­ature to date, information about the dose to the parotid glands and the volume irradi­ated is very limited or absent. In the first of two 'positive' studies, Lajtman et al. [36] only observed a positive effect of pilocarpine in the group of patients treated with a partial irradiation of the parotid gland. In the other positive study by Haddad et al. [39] both parotid glands, including their upper part, were within the irradiation fields and the minimum doses given were 40 Gy. Although in both studies exact information on volume, mean or maximum dose or the dose distribution was not provided, they both 
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support our suggestion that pilocarpine treatment during radiotherapy is beneficial only when a substantial part of the parotid gland (and thus the progenitor cells) was outside the high dose area and/or when the mean dose was relatively low. In the six 'negative' studies, the volume of the parotid gland irradiated to doses > 50 Gy or the mean dose all seemed to be higher than in the positive trials, varying from >50 % of the parotid volume receiving > 50 Gy [40, 42] or >66% of the parotid gland volume receiving >50 Gy [41] to both parotid glands (100%?) receiving >50 Gy [37, 38]. All these 5 papers, however, lack precise information on the calculations of these doses and vol­umes. Only in the last 'negative' study by Rode et al. [35], dose-volume parameters were precisely defined. Using diagnostic CT and simulator film irradiated volumes were determined and subsequently the doses were calculated using three cross-sec­tions through the irradiated volume (and probably through the region of the parotid glands). The mean dose in the pilocarpine treated group in this study was 56.4 Gy, implying that lack of an effect of pilocarpine was probably due to the high doses to rather large volumes, outside the dose range where pilocarpine is effective in reduc­ing hyposalivation (chapter 7). So combining all these clinical data, it seems that there is an optimal dose range and optimal irradiated volume of the parotid gland, in which pilocarpine will be (most) effective. The exact dose/volume range within which pilocarpine is probably most effective remains to be determined, but it is estimated that it must be within the range of a mean dose to the parotid gland of 40 to 50-55 Gy. With IMRT, the mean dose to the parotid glands is aimed to be < 30 Gy. Although the patients in our study were not treated with IMRT techniques, considering the data from our study, no or very little beneficial effect can be expected for patients in whom the mean parotid dose remains below this threshold. However, also with IMRT it is not always possible to stay below mean doses of 40 Gy. Moreover, using IMRT, the dose distribution within the parotid glands will likely be quite different compared with the old techniques with two lateral opposed beams and hence even further increase the conditions under which pilo­carpine treatment may be beneficial. All in all, it is suggested that whenever the mean dose to the parotid glands goes beyond 40 Gy, administration of pilocarpine is likely beneficial and should be offered to the patient. 
Conclusions and future prospective for pilocarpine The best way to limit radiation damage to the salivary glands is to keep the radiation dose to the salivary glands as low as possible, i.e. below the threshold for radiation­induced damage to salivary gland tissue resulting in xerostomia. IMRT is a new radia­tion technique based on this philosophy and should be the standard technique for all 
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head and neck patients undergoing, primary or postoperative, (chemo) radiotherapy for head and neck cancer, in particular when bilateral radiotherapy of the neck is indi­cated. Preliminary data from our Department [unpublished data] and others [46], clearly indicate that the use of protons may lead to further reduction of the dose to the salivary glands. Although a TD50 for the parotid gland is somewhere between 26 and 39 Gy, still some loss of salivary function will appear even after low doses given with IMRT. A threshold dose for xerostomia probably does not exist and even at low doses some loss of salivary gland function will be present. The results of the randomised study did not show a significant benefit of oral pilocarpine during the course of radiotherapy. However, the results of the subset analysis indicate that pilocarpine is beneficial among those in which the mean parotid dose exceeds the 40 Gy, which is in agreement with our preclinical findings. Although, from a methodological point of view, no defin­itive conclusions can be drawn from this subset analysis, we feel that pilocarpine should be offered to this specific subset of patients, considering that pilocarpine is cheap and easy to administer with only mild side effects on the one hand, and that the probability of salivary dysfunction is high and has important additional side effects and a negative impact on health-related quality of life on the other hand. Moreover, with the clinical introduction of IMRT, the proportion of patients with a mean parotid dose > 40 Gy will be too small to ensure sufficient accrual in a subsequent phase III trial within a reasonable period of time. 
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Samenvatting en discussie Een gevoel van een droge mond (xerostomie), gerelateerd aan een verminderde speek­selsecretie (hyposialie), is de meest frequente klacht na radiotherapie voor de behande­ling van een tumor in het hoofd-halsgebied. In verschillende studies is aangetoond dat xerostomie een belangrijke negatieve invloed heeft op de kwaliteit van leven [1;2]. Speek­sel speelt een belangrijke rol bij een aantal functies zoals het spreken, de smaak, het zacht maken van eten, de vorming van een voedselbolus, het slikken, de zelfreiniging van de mond, het doden e.g. remmen van de groei van bacterien en de bescherming van het slijmvlies [3;4]. Pilocarpine is een medicament dat de secretie van speeksel stimu­leert en de stralingsschade aan speekselklierweefsel zou kunnen verminderen bij toe­diening tijdens de radiotherapie. In dit proefschrift is de toegevoegde waarde van pilocarpine toediening tijdens de radiotherapie bij de preventie en de vermindering van straling ge'induceerde schade aan speekselklierweefsel nader onderzocht. De afgelopen decennia is veel (pre )klinisch onderzoek verricht naar het ontwikkelen van nieuwe strategieen om stralingsge'induceerde schade aan speekselklierweefsel te ver­minderen (hoofdstuk 2). Dit onderzoek heeft geresulteerd in meer gedetailleerde informa­tie met betrekking tot de patho-fysiologische mechanism en die een rol spelen bij stralingsge'induceerde schade aan de speekselklieren. Deze gegevens zijn vooral atkomstig uit dierexperimentele studies en zijn daarom niet een op een te vertalen naar de mens. Uit het in ons laboratorium toegepaste rattenmodel - mannelijke albino Wistar rat­ten die lokaal, ter plaatse van de speekselklieren, werden bestraald met enkelvoudige en/of gefractioneerde stralingsdoses - zijn vier verschillende fasen naar voren geko­men die het ontwikkelen van stralingsschade aan zowel de glandula parotis als de glandula submandibularis karakteriseren [5;6]. De acute fase (dag o-10 na bestraling met een enkelvoudige dosis van 15 Gy) wordt gekenmerkt door een snel optredend ver­lies van waterige secretie zonder dat er duidelijk sprake is van celverlies. Deze secretie­daling is waarschijnlijk het gevolg van een verstoring van de signaaltransductie die aan de basis ligt van de waterige secretie [7]. De vroege fase (dag 10-60) wordt gekenmerkt door verlies van acinaire cell en als een gevolg van membraanschade en een onvol­doende compensatie van dit celverlies door celproliferatie. Gedurende de intermedi­aire fase (dag 60-120) warden geen grote veranderingen in het aantal cellen en de 
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speekselproductie waargenomen. De late fase ( dag 120-240) wordt vooral gekenmerkt door een verdere afname van proliferatie van de speekselkliercellen (het is onbekend of dit de progenitor- en/of de stamcellen betreft). Deze verdere afname van celprolife­ratie resulteert in een verlies van acinaire cellen en een toename van de fibreuze com­ponent [6-8]. Deze veranderingen leiden tot een verder verlies van de speekselproductie en een vermindering van de amylase productie. Met andere woorden, er blijkt bij het proefdier sprake te zijn van twee mechanismen die ten grondslag liggen aan het stra­lingsgei'nduceerde verlies van de speekselklierfunctie. Initieel wordt de cellulaire func­tie negatief bei'nvloed ten gevolge van selectieve membraanschade, later ontstaat een tekort aan functionerende, secretoire cellen ten gevolge van verlies van progenitor­en/of stamcellen en schade aan de cellulaire omgeving. De indruk bestond, uit zowel eigen ervaringen als de literatuur, dat bij patienten die werden blootgesteld aan een volledige serie gefractioneerde bestralingen, verlies van de speekselproductie al bij een relatieflage cumulatieve dosis leek op te treden. Daarom werd, om de stralingsgei'nduceerde veranderingen in de speekselproductie van de glan­dula submandibularis/glandula sublingualis en de glandula parotis te bepalen, selectief speeksel opgevangen van de grote speekselldieren bij patienten die bestraald werden voor een tumor in het hoofd-halsgebied. De speekselsecretie werd zowel tijdens als tot drie maanden na een serie conventioneel gefractioneerde radiotherapie gemeten. Het speeksel van de glandula submandibularis en de glandula sublingualis werd gezamen­lijk verzameld, terwijl het speeksel van de glandula parotis separaat werd opgevangen. In dit onderzoek (hoofdstuk 5) werd een verlies in de speekselsecretie van >80% gedurende de eerste twee weken van de behandeling waargenomen. Deze resultaten ton en aan dat al bij een lage cumulatieve bestralingsdosis, zelfs beneden de beschreven en algemeen geaccepteerde tolerantie dosis voor de glandula parotis, een TD50 (= de dosis op de gehele glandula parotis waarbij er een complicatie kans van 50% bestaat) van 26-31 Gy, er een substantieel verlies van de speekselsecretie aantoonbaar is. Dit vroege verlies van de speekselsecretie is waarschijnlijk omkeerbaar en het resultaat van een verstoorde sig­naaltransductie [7]. Tevens werd, zowel tijdens als tot drie maanden na de radiotherapie, geen verschil in de afname van de speekselsecretie tussen de glandula parotis en de glandula submandibularis/sublingualis aangetroffen. Deze bevinding duidt op een ver­gelijkbare stralingsgevoeligheid van de grate speekselklieren. Hierbij moet word en opgemerkt dat de vermindering van de speekselsecretie van de glandula submandibula­ris/sublingualis en de verspreid onder het slijmvlies van de mondkeelholte gelegen ldeine speekselkliertjes een belangrijke rol spelen bij het ontstaan van xerostomie [9-11]. In tegenstelling tot de glandula parotis dragen de glandula submandibularis, de glan­dula sublingualis en ldeine speekselkliertjes significant bij aan de speekselsecretie in rust en tijdens minimale stimulatie; deze omstandigheden zijn het overgrote deel van de dag aanwezig. De argumentatie dat stralingsschade aan de glandula submandibula-
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ris/sublingualis voor het ontstaan van xerostomie van belang is, wordt ondersteund door de uitkomsten van een aantal klinische studies waaruit blijkt dat de toegediende stra­lingsdosis aan deze speekselklieren een voorspellende waarde heeft voor de emst van de xerostomie. Het is daarom belangrijk dat er in toekomstige studies meer aandacht aan bescherming van deze speekselklieren wordt besteed [9;11;12]. Vermindering van de stralingsschade aan het speekselklierweefsel kan op verschil­lende manieren worden verkregen. Het sparen van speekselklierweefsel door een ver­mindering van de stralingsdosis en/of het bestraalde volume. Dit kan bijvoorbeeld door het gebruik te maken van nieuwe bestralingstechnieken zoals de 'intensiteit gemoduleerde radiotherapie' (IMRT) [13-17] waarbij het mogelijk is om de stralings­ge'induceerde schade aan de speekselklieren en de daaraan gerelateerde xerostomie te verminderen. Soms is adequate sparing van de speekselklieren met behulp van deze nieuwe techniek niet mogelijk bijvoorbeeld door de ligging van de primaire tumor en/of de aanwezigheid van dubbelzijdige halskliermetastasen en/of omdat deze nieuwe techniek nog niet klinisch beschikbaar is op alle radiotherapie afdelingen. Dan zou het gebruik van radioprotectieve farmaca een belangrijk altematief kunnen zijn [4]. Bescherming van speekselklierweefsel tegen de effecten van ioniserende stra­ling kan o.a. plaatsvinden met behulp van selectieve protectoren zoals de 'radicale sca­venger' amifostine. In gerandomiseerde klinische studies en in dierexperimenten is het gebruik van amifostine effectief gebleken [18-28]. Nadelen van het gebruik van ami­fostine zijn de dagelijkse, invasieve toedieningsvorm (intraveneus of subcutaan), de hoge kosten en de bijwerkingen zoals bloeddrukdalingen, overgeven en allergische reacties [29]. Hoewel amifostine de incidentie van het ontwikkelen van xerostomie met 
20-30% kan verminderen blijft een relatief grote groep patienten klachten houden. De eerder genoemde nadelen en de vermeende tumor beschermende werking [30], heb­ben het routine gebruik van amifostine in de kliniek tot op heden in de weg gestaan. Uit dierexperimentele studies is naar voren gekomen dat ook de toediening van pilo­carpine voorafgaande aan de bestraling van de glandula parotis kan leiden tot een gerin­gere afname van de speekselsecretie [31;32]. Initiele, niet-gerandomiseerde studies bij patienten met een tumor in het hoofd-halsgebied lieten een overeenkomstig effect zien 
[33;34], maar in daama uitgevoerde gerandomiseerde studies werden tegenstrijdige resultaten gezien [35-42]. Deze tegenstrijdige resultaten kunnen verklaard worden door het beperkte aantal patienten in sommige studies en de verschillend gekozen eindpun­ten (subjectieve en/of objectieve monddroogheid, onvoldoende variatie in het bestraalde volume en/of de cumulatieve dosis, het ontbreken van een exacte berekening van het bestraalde volume van het speekselklierweefsel en de cumulatieve dosis op dit weefsel). Zoals beschreven in de inleiding (hoofdstuk 1), is in dit proefschrift vooral gekeken naar de mogelijke rol van pilocarpine bij het verminderen van stralingsge'induceerde afname van de speekselsecretie. Pilocarpine is een goedkoop, eenvoudig toe te dienen, 
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relatief veilig medicijn met mil de bijwerkingen [43] en zou een ideale stof kunnen zijn om in de klinische praktijk te gebruiken. Dit, op voorwaarde dat de effectiviteit van pilocarpine om te komen tot een afname van de stralingsge"induceerde vermindering van de speekselsecretie voldoende kan worden aangetoond. De effectiviteit van pilo­carpine om de stralingsschade aan speekselklierweefsel te verminderen is zowel in het rattenmodel als in een grote gerandomiseerde studie bij patienten met een tumor in het hoofd-halsgebied onderzocht. In hoofdstuk 3 worden de resultaten beschreven van met pilocarpine voorbehan­delde ratten, waarbij het effect van pilocarpine toediening op het vroege en het late stralingsge"induceerde functieverlies van de glandula parotis is onderzocht. In de acute fase bleek activatie van de muscarine receptoren en de second messengers door pilo­carpine de proliferatie van overlevende progenitor- en/of stamcellen te stimuleren. Dit resulteerde in een toename van het aantal acinaire cellen, waardoor het celverlies door de bestraling werd hersteld en de speekselsecretie tot 120 dagen na de bestraling ten opzichte van de controlegroep (wel bestraling, geen pilocarpine) significant was toege­nomen. In de late fase ( 120-240 dagen) werd wel een gedeeltelijk herstel van de speek­selsecretie gezien na een enkele bestralingsdosis van 10 of 15 Gy, maar niet na een enkele bestralingsdosis 2'.: 20 Gy. Tevens werd een stimulerend effect gezien in de pilo­carpine behandelde ratten op de speekselsecretie van de afgeschermde, contralaterale speekselklier. Dit stimulerende effect was het meest uitgesproken na enkelvoudige hoge bestralingsdoses 2'.: 20 Gy en bleek aan te houden tot in de late fase. Het gedeelte­lijke, late herstel van de speekselsecretie, na voorbehandeling met pilocarpine, liep parallel met de toename van het aantal acinaire cellen. Deze resultaten ondersteunen het idee dat na de acute fase het effect van pilocarpine is toe te schrijven aan de stimu­latie van de celproliferatie. Deze hypothese wordt ook ondersteund door de resultaten die beschreven staan in hoofdstuk 4, waarbij met behulp van een proliferatiemarker kleuring PCNA (Proliferating Cell Nuclear Antigen) 10 en 20 dagen na de bestraling een toename kon worden gezien van de proliferatie van zowel acinaire als 'intercalated duct' cellen. Uit deze resultaten kon worden opgemaakt dat pilocarpine waarschijnlijk alleen binnen een bepaald dosis/volume gebied werkzaam is. In het lage dosis/volume gebied treedt er slechts beperkte schade op, toediening van pilocarpine leidt dan niet tot een zodanige extra stimulatie van de proliferatie dat in de pilocarpine groep meer herstel van functie wordt gezien dan in de placebogroep. Bij zeer hoge doses is de schade zo groot dat er geen overlevende cellen zijn die door de pilocarpine tot prolife­ratie kunnen worden gestimuleerd en om het stralingsge"induceerde verlies aan speek­selklierfunctie te kunnen herstellen. Met andere woorden, het beschermende effect van pilocarpine wordt alleen gezien als voldoende progenitor- en/of stamcellen na de bestraling overleven, zodat pilocarpine tot voldoende extra stimulatie van de celpro­liferatie kan leiden en daarmee het celverlies kan compenseren. Pilocarpine moet 
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daarom niet als een klassieke radioprotector worden beschouwd maar als een stimula­tor van de celproliferatie voor de overlevende progenitor- en/of stamcellen. In het rattenmodel werd een uniforme dosis over de hele speekselklier gegeven, bij patienten is er meestal sprake van een dosisgradient over de speekselklier. Daarom is het essentieel om de dosisverdeling in zijn geheel door middel van dosis-volume histo­grammen (DVH) te beoordelen om meer informatie te krijgen over lage dosis gebieden. Hierdoor is het mogelijk een indruk te krijgen over het percentage overlevende progeni­tor-en/of stamcellen die door pilocarpine tot proliferatie kunnen worden gestimuleerd. Om deze re den werd het effect van pilocarpine onderzocht in een studie (hoofdstuk 7) waarbij de patienten in drie verschillende dosis/volume groepen werden ingedeeld. Bij de patienten in deze gerandomiseerde studie waren de glandula submandibula­ris tijdens de halsklierdissectie verwijderd of lagen ze volledig in het hoge stralingsdo­sis gebied. Het primaire eindpunt in deze studie was de 'parotid flow rate complication probability (PFCP), gedefinieerd als een afname van de speekselsecretie tot minder dan 25% van de uitgangswaarde ( dit eindpunt wordt in de literatuur meestal gebruikt om de normale weefselschade kans (=NTCP) aan de speekselklieren te definieren). Secundaire eindpunten waren de xerostomie scores bepaald met de LENT (Late Effects on Normal Tissue) SOMA (Subjective Objective Management Analytic) score en een patientgebon­den xerostomie score verkregen door middel van een vragenlijst. Analyse van de onder­zochte populatie in zijn geheel laat zien dat er geen statistisch significante verschillen werden gevonden in de PFCP, de LENT SOMA score en de patientgebonden xerostomie score tussen de pilocarpine en de placebo groep. Bij de groep patienten die een gemid­delde dosis van >40 Gy op de glandula parotis ontvingen werd echter wel een verschil in de PFCP tussen de pilocarpine en de placebo groep gevonden. Dit bleek het meest uit­gesproken en statistisch significant na 1 jaar. Voor de LENT SOMA score en de patient­gebonden xerostomie score werden dezelfde trends gezien. Er werden echter geen verschillen gevonden bij de patienten behandeld met pilocarpine en met placebo met een gemiddelde dosis �40 Gy. Hierbij moet wel worden opgemerkt dat de PFCP in deze laatste groep al erg laag was (tussen de 10 en 20 %), zodat er weinig ruimte over was voor het waarnemen van een eventuele verbetering door de pilocarpine toediening. Hoewel deze studie niet ontworpen was om een dergelijke subgroepanalyse uit te voeren, sugge­reren deze uitkomsten dat er een bepaalde hoeveelheid schade aanwezig moet zijn voordat een positief 'sparend' effect van pilocarpine op de speekselsecretie kan worden waargenomen. Deze resultaten van de klinische studie zijn in overeenstemming met de voorafgaand genoemde dierstudies [6;31;32]. Maar er kan er geen effect van pilocarpine toediening worden verwacht indien de schade boven een bepaald niveau uitkomt, waar­door er een tekort aan prolifererende cellen optreedt en de schade niet meer hersteld kan worden (zie hoofdstuk 3). In de tot op heden gepubliceerde gerandomiseerde studies in de medische litera-
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tuur is de informatie over de cumulatieve dosis op het bestraalde volume van de glan­dula parotis beperkt of ontbreekt helemaal. In de positieve studie van Lajtman et al. 
[36] werd alleen een positief effect van het toedienen van pilocarpine tijdens de bestra­lingsperiode gezien bij de patienten bij wie de glandula parotis slechts gedeeltelijk in het bestralingsveld had gelegen. In de positieve studie van Haddad et al. [39] waren beide glandula parotis geheel in het bestralingsveld gelegen en was de cumulatieve dosis op deze speekselklieren minimaal 40 Gy. Hoewel in beide studies geen exacte gegevens over het bestraalde volume, noch van de gemiddelde, minimum of maxi­mum dosis of de dosisverdeling in de glandula parotis staan beschreven, bevestigen de bevindingen uit beide studies de hypothese dat pilocarpine alleen werkt indien een substantieel deel van de glandula parotis buiten het hoge dosis gebied is gelegen (en daarmee de progenitor- en/of stamcellen) en/of de gemiddelde dosis relatief laag is. In de zes studies die geen betere restfunctie van de glandula parotis laten zien na toedie­ning van pilocarpine gedurende de bestralingsperiode, lijken het volume van de glan­dula parotis dat bestraald is met een dosis >50 Gy of de gemiddelde dosis op de glandula parotis hoger te zijn dan in de positieve studies. Voor zover de dosis/volume gegevens uit deze studies is op te maken, varieren ze van >50 % van het volume van de glandula parotis dat > 50 Gy ontvangt [40;42], >66% van dit volume dat >50 Gy ontvangt 
[41], tot een dosis van >50 Gy over, naar het schijnt, het totale volume beide glandula parotis [37;38]. Helaas ontbreekt in deze publicaties de exacte informatie over de gemiddelde cumulatieve dosis en het bestraalde volumen van de glandula parotis. Alleen in de 'negatieve' studie van Rode et al. [35] worden de dosis/volume gegevens vermeld. De gemiddelde cumulatieve dosis in de pilocarpine behandelde groep was 56,4 Gy, waardoor het ontbreken van het beschermende effect van pilocarpine waar­schijnlijk het gevolg was van de hoge cumulatieve dosis op een groot volume van de glandula parotis. De door hen toegepaste bestralingsvelden valt daardoor buiten het dosis/volume ge hied waar pilocarpine effectief is in het verminderen van de stralings­ge'induceerde afname van de speekselsecretie (hoofdstuk 7). Wanneer onze onderzoeksgegevens worden vergeleken met de bevindingen uit de literatuur, lijkt er sprake te zijn van een optimale dosis/volume verhouding in de glan­dula parotis waarbij pilocarpine het meest effectief is. Het exacte dosis/volume gebied moet nog nader worden bepaald, maar ligt waarschijnlijk in de orde van een gemid­delde cumulatieve dosis in de glandula parotis van 40 tot 50-55 Gy. Met IMRT wordt naar een gemiddelde dosis in de glandula parotis van <30 Gy gestreefd. Hoewel de patienten in de studie niet met IMRT zijn behandeld is gezien de uitkomst van de stu­die geen of weinig effect van pilocarpine te verwachten bij pa ti en ten bij wie de gemid­delde dosis beneden deze grens blijft. Het is zelfs niet altijd mogelijk om met IMRT beneden een gemiddelde dosis van 40 Gy te blijven. Verder is de dosisverdeling bij een IMRT plan totaal verschillend ten opzichte van de conventionele techniek met twee 
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laterale velden, waardoor het werkingsgebied van pilocarpine kan veranderen. De sug­gestie dat pilocarpine behandeling effectief is boven een gemiddelde dosis > 40 Gy maakt dat het aan deze patienten zou moeten worden aangeboden. 
Conclusies en toekomstig perspectief voor pilocarpine De beste manier om stralingsgei'nduceerde schade aan de speekselklieren te beperken is de cumulatieve bestralingsdosis zo laag mogelijk te houden. Indien de dosis waarbij stralingschade aan de speekselklier optreedt, wordt overschreden zal deze aanleiding geven tot een zodanige afname van de speekselsecretie dat het merendeel van de patienten xerostomie ervaart. IMRT is en nieuwe techniek die op deze filosofie is geba­seerd en zou volgens de huidige stand van de wetenschap de standaard behandeling moeten zijn voor alle patienten met een tumor in het hoofd-halsgebied die primaire of postoperatieve (chemo)radiotherapie ondergaan. Vooral als een dubbelzijdige bestra­ling van de hals is gei'ndiceerd. De eerste onderzoeksgegevens [eigen ongepubliceerde data] naar het gebruik van protonen, laten een verdere afname van de stralingsdosis in de speekselklieren zien [46]. Hoewel een TD50 voor het optreden van irreversibele stralingsschade aan glandula parotis vermoedelijk tussen 26 en 39 Gy ligt, blijkt ook na lagere doses, zoals o.a. wor­den gegeven met IMRT, toch enig functieverlies op te treden. Een echte drempeldosis voor het ontstaan van een verminderde speekselsecretie en daarmee samenhangende xerostomie na radiotherapie bestaat waarschijnlijk niet en zelfs na lage cumulatieve doses is enig functieverlies aanwezig. De gerandomiseerde studie liet voor de gehele groep geen voordeel van pilocarpine behandeling tijdens de radiotherapie zien. Er is echter wel een voordeel aantoonbaar voor een subgroep waarbij de gemid­delde cumulatieve bestralingsdosis meer dan 40 Gy bedroeg, wat in overeenstemming is met de preklinische resultaten. Hoewel het vanuit methodologisch oogpunt niet mogelijk is definitieve conclusies te trekken, zijn wij van mening dat pilocarpine moet worden aangeboden aan de patienten die tot deze subgroep behoren. De kans op ver­lies van speekselklierfunctie bij patienten die in het hoofd-halsgebied bestraald wor­den is groot en heeft een nadelige invloed op de kwaliteit van leven en maakt dit tot een realistische aanpak. Pilocarpine is een goedkoop en eenvoudig is toe te dienen medicament met geringe bijwerkingen. Met de introductie van de IMRT is het percen­tage patienten met een cumulatieve gemiddelde dosis > 40 Gy op de glandula parotis sterk afgenomen. Het verrichten van een aanvullende fase III studie met een overeen­komstige onderzoeksopzet als beschreven in hoofdstuk 7 binnen een afzienbare peri­ode zal erg lastig zijn. 
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